Analogic (ALOG) 10-Q 7 Jun 17 2017 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Apr. 30, 2017	May 30, 2017
Document And Entity Information [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Apr. 30, 2017
Document Fiscal Year Focus	2,017
Document Fiscal Period Focus	Q3
Trading Symbol	ALOG
Entity Registrant Name	ANALOGIC CORP
Entity Central Index Key	6,284
Current Fiscal Year End Date	--07-31
Entity Filer Category	Large Accelerated Filer
Entity Common Stock, Shares Outstanding		12,470,526

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($) $ in Thousands	Apr. 30, 2017	Jul. 31, 2016
Current assets:
Cash and cash equivalents	$ 158,633	$ 118,697
Accounts receivable, net of allowance for doubtful accounts of $1,160 and $1,070 as of April 30, 2017 and July 31, 2016, respectively	93,560	112,412
Inventory	144,344	145,513
Income tax receivable	1,902	3,004
Prepaid expenses and other current assets	10,229	9,178
Total current assets	408,668	388,804
Property, plant, and equipment, net	105,539	107,790
Intangible assets, net	27,406	45,194
Goodwill	2,344	73,915
Deferred income taxes	19,051	10,671
Other assets	4,669	6,523
Total assets	567,677	632,897
Current liabilities:
Accounts payable	29,211	28,575
Accrued employee compensation and benefits	17,906	18,108
Accrued income tax	2,361	1,610
Accrued warranty	6,205	6,296
Accrued restructuring charges	2,442	5,248
Deferred revenue	4,702	5,359
Customer deposits	4,028	3,476
Contingent consideration		4,534
Other current liabilities	5,478	5,261
Total current liabilities	72,333	78,467
Long-term liabilities:
Accrued income taxes, net of current portion	1,858	2,174
Contingent consideration, net of current portion		7,705
Other long-term liabilities	11,772	13,374
Total long-term liabilities	13,630	23,253
Guarantees, commitments and contingencies (Note 15)
Stockholders’ Equity:
Common stock, $0.05 par value; 30,000,000 shares authorized and 12,471,169 shares issued and outstanding as of April 30, 2017; 30,000,000 shares authorized and 12,396,765 shares issued and outstanding as of July 31, 2016	622	619
Capital in excess of par value	156,635	149,005
Retained earnings	335,317	390,013
Accumulated other comprehensive loss	(10,860)	(8,460)
Total stockholders’ equity	481,714	531,177
Total liabilities and stockholders’ equity	$ 567,677	$ 632,897

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	Apr. 30, 2017	Jul. 31, 2016
Statement Of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 1,160	$ 1,070
Common stock, par value	$ 0.05	$ 0.05
Common stock, shares authorized	30,000,000	30,000,000
Common stock, shares issued	12,471,169	12,396,765
Common stock, shares outstanding	12,471,169	12,396,765

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Net revenue:
Product	$ 120,791	$ 126,376	$ 371,373	$ 366,443
Engineering	1,371	1,604	3,448	4,354
Total net revenue	122,162	127,980	374,821	370,797
Cost of sales:
Product	68,667	71,340	210,149	202,410
Engineering	1,334	1,707	3,180	3,736
Total cost of sales	70,001	73,047	213,329	206,146
Gross profit	52,161	54,933	161,492	164,651
Operating expenses:
Research and product development	14,900	16,464	46,962	50,269
Selling and marketing	16,356	15,796	51,894	46,278
General and administrative	10,377	13,208	27,978	48,712
Restructuring	2,080	1,839	2,379	8,269
Asset impairment charges	73,051		83,474
Total operating expenses	116,764	47,307	212,687	153,528
(Loss) income from operations	(64,603)	7,626	(51,195)	11,123
Other income (expense), net	57	(934)	(357)	(4,899)
(Loss) income before income taxes	(64,546)	6,692	(51,552)	6,224
(Benefit) provision for income taxes	(4,882)	1,722	(1,934)	2,863
Net (loss) income	$ (59,664)	$ 4,970	$ (49,618)	$ 3,361
Net (loss) income per common share:
Basic	$ (4.78)	$ 0.40	$ (3.98)	$ 0.27
Diluted	$ (4.78)	$ 0.40	$ (3.98)	$ 0.27
Weighted average shares outstanding:
Basic	12,486	12,392	12,457	12,412
Diluted	12,486	12,553	12,457	12,623
Dividends declared and paid per share	$ 0.10	$ 0.10	$ 0.30	$ 0.30

Consolidated Statements of Comp

Consolidated Statements of Comprehensive Income - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Statement Of Income And Comprehensive Income [Abstract]
Net (loss) income	$ (59,664)	$ 4,970	$ (49,618)	$ 3,361
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment, net of tax	178	3,551	(2,415)	303
Unrecognized gain on pension benefits, net of tax	58	26	167	76
Unrealized (loss) gain on foreign currency forward contracts, net of tax	(324)	373	(153)	358
Total other comprehensive (loss) income, net of tax	(88)	3,950	(2,401)	737
Total comprehensive (loss) income	$ (59,752)	$ 8,920	$ (52,019)	$ 4,098

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($) $ in Thousands	9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016
CASH FLOWS FROM OPERATING ACTIVITIES:
Net (loss) income	$ (49,618)	$ 3,361
Adjustments to reconcile net income to net cash provided by operating activities:
Benefit from deferred income taxes	(8,402)	(2,681)
Depreciation and amortization	19,221	17,157
Asset impairment charges	83,474
Share-based compensation expense	6,450	7,144
Write down of demo equipment to net realizable value	1,557	2,496
Provision for excess and obsolescence inventory	287	775
Excess tax benefit from share-based compensation	(158)	(300)
Change in fair value of contingent consideration	(10,238)
Provision for doubtful accounts, net of recovery	88	67
(Gain) loss on sale of property, plant and equipment	(57)
Net changes in operating assets and liabilities:
Accounts receivable	18,295	23,518
Inventory	(5,547)	(24,160)
Prepaid expenses and other assets	596	(2,194)
Accounts payable	608	2,006
Accrued liabilities	(2,845)	11,573
Deferred revenue	(641)	(743)
Customer deposits	554	(85)
Accrued income taxes and income taxes receivable	1,174	(3,839)
Other liabilities	(1,423)	796
Cash paid for contingent consideration	100
NET CASH PROVIDED BY OPERATING ACTIVITIES	53,275	34,891
CASH FLOWS FROM INVESTING ACTIVITIES:
Additions to property, plant, and equipment	(7,741)	(9,664)
Acquisition of businesses, net of cash acquired		(8,026)
Proceeds from the sale of property, plant, and equipment	30	66
NET CASH USED IN INVESTING ACTIVITIES	(7,711)	(17,624)
CASH FLOWS FROM FINANCING ACTIVITIES:
Issuance of stock pursuant to exercise of stock options, employee stock purchase plan, restricted stock plans, and non-employee director stock plan	3,090	3,397
Repurchase of common stock	(1,584)	(11,793)
Shares repurchased for taxes for vested employee restricted stock grants	(1,128)	(1,774)
Excess tax benefit from share-based compensation	158	300
Dividends paid to shareholders	(3,771)	(3,726)
Cash paid for financing cost		(499)
Contingent consideration paid for business acquisitions	(1,900)
NET CASH USED IN FINANCING ACTIVITIES	(5,135)	(14,095)
EFFECT OF EXCHANGE RATE CHANGES ON CASH	(493)	1,152
NET INCREASE IN CASH AND CASH EQUIVALENTS	39,936	4,324
CASH AND CASH EQUIVALENTS, BEGINNING OF PERIOD	118,697	123,800
CASH AND CASH EQUIVALENTS, END OF PERIOD	158,633	$ 128,124
Supplemental disclosures of cash flow information:
Non-cash transfer of demonstration inventory to fixed asset	$ 3,506

Basis of presentation

Basis of presentation	9 Months Ended
	Apr. 30, 2017
Accounting Policies [Abstract]
Basis of presentation	1. Basis of presentation Throughout this Quarterly Report on Form 10-Q, unless the context states otherwise, the words “we,” “us,” “our” and “Analogic” refer to Analogic Corporation and all of its subsidiaries taken as a whole, and “our board of directors” refers to the board of directors of Analogic Corporation. Our unaudited consolidated financial statements presented herein have been prepared pursuant to the rules of the United States Securities and Exchange Commission, or SEC, for quarterly reports on Form 10-Q. Preparing financial statements requires us to make estimates and assumptions that affect the reported amounts of assets, liabilities, revenue, and expenses. We report our financial condition and results of operations on a fiscal year basis ending on July 31st of each year. The nine months ended April 30, 2017 and 2016 represent the third quarters of fiscal years 2017 and 2016, respectively. In our opinion, the accompanying unaudited consolidated financial statements contain all adjustments (consisting solely of normal recurring adjustments) necessary for a fair statement of the results for all interim periods presented. The results of operations for the three and nine months ended April 30, 2017 are not necessarily indicative of the operating results for the full year. These statements should be read in conjunction with the consolidated financial statements and notes thereto for the fiscal year ended July 31, 2016, or fiscal year 2016, included in our Annual Report on Form 10-K as filed with the SEC on September 27, 2016. The year-end balance sheet data was derived from audited financial statements, but does not include all disclosures required by generally accepted accounting principles, or GAAP, in the United States of America. Consolidation The unaudited consolidated financial statements presented herein include our accounts and those of our subsidiaries, all of which are wholly owned. All intercompany accounts and transactions have been eliminated in consolidation. In determining whether we are the primary beneficiary of an entity and therefore required to consolidate, we apply a qualitative approach that determines whether we have both (1) the power to direct the economically significant activities of the entity and (2) the obligation to absorb losses of, or the right to receive benefits from, the entity that could potentially be significant to that entity. We have not been required to consolidate the activity of any entity due to these considerations. Reclassifications and revisions to prior period financial statements Certain financial statement items have been reclassified to conform to the current period presentation. We separately presented write down of demo equipment to net realizable value and provision for excess and obsolescence inventory on our April 30, 2016 Consolidated Statements of Cash Flows to conform to the current period presentation. There was no impact on our Consolidated Statements of Operations as a result of these reclassifications.

Recent accounting pronouncement

Recent accounting pronouncements	9 Months Ended
	Apr. 30, 2017
Accounting Changes And Error Corrections [Abstract]
Recent accounting pronouncements	2. Recent accounting pronouncements Accounting pronouncements issued and recently adopted None. Accounting pronouncements issued and not yet effective Clarifying the Definition of a Business In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business.” The amendments provide the requirements needed for a set to be a business and establish a practical way to determine when a set is not a business. To be considered a business, an acquisition would have to include an input and a substantive process that together significantly contribute to the ability to create outputs. An output is the result of inputs and substantive processes that provide goods or services to customers, other revenue, or investment income, such as dividends and interest. The amendments narrow the definition of outputs and align it with how outputs are described in Topic 606 “Revenue from Contracts with Customers”. The amendments are effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The standard will be effective for us in fiscal years beginning August 1, 2018. We are currently evaluating the impact of the adoption of this update on our consolidated financial statements. Classification of Certain Cash Receipts and Cash Payments In August 2016, the FASB issued ASU No. 2016-15, “ Statement of Cash Flows (Topic 230).” The amendments provide guidance on the eight specific cash flow statement presentation and classification issues as follows: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. The amendments are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The standard will be effective for us in the first quarter of our fiscal year ending July 31, 2019. We are currently evaluating the impact of the adoption of this update on our consolidated financial statements. Improvements to employee share-based payment accounting In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting,” which amends ASC 718, “Stock Based Compensation.” The amendments require that all excess tax benefits be recorded as an income tax benefit or expense in the income statement and be classified as an operating activity in the statement of cash flows. Entities may also elect to estimate the amount of forfeitures or recognize them as they occur. The amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The standard will be effective for us in the first quarter of our fiscal year ending July 31, 2018 and early adoption is permitted. We are currently evaluating the impact of the adoption of this update on our consolidated financial statements. Leases In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”. The standard requires lessees to recognize assets and liabilities for most leases on the balance sheet. For income statement purposes, the standard requires leases to be classified as either operating or finance. The standard is effective for annual and interim periods beginning after December 15, 2018. Early adoption is permitted. The standard will be effective for us in the first quarter of our fiscal year ending July 31, 2020. Adoption requires application of the new guidance for all periods presented. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements. Revenue from contracts with customers In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. This update affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. This update will supersede existing revenue recognition requirements and most industry-specific guidance. This update also supersedes some cost guidance, including revenue recognition guidance for construction-type and production-type contracts. The update’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. This update should be applied either on a retrospective or modified retrospective basis. This update was originally effective for us in the first quarter of our fiscal year ending July 31, 2018. Early adoption was not permitted. In August 2015, the FASB approved a one year delay of the effective date of the new revenue standard for public entities. Therefore, this update would be effective for us in the first quarter of our fiscal year ending July 31, 2019. The standard permits entities to early adopt, but only as of the original effective date (i.e. one year earlier). We are expected to adopt the new standard in the first quarter of our fiscal year 2019 effective August 01, 2018. We are still in the early stage of assessing the adoption method and analyzing the impact of the adoption of this update on our consolidated financial statements. We are unable to quantify the impact at this time. We established a project plan and an implementation team. The implementation team continues to apprise both management and the Audit Committee of project status on a recurring basis.

Accounts receivable, net

Accounts receivable, net	9 Months Ended
	Apr. 30, 2017
Risks And Uncertainties [Abstract]
Accounts receivable, net	3. Accounts receivable, net Our accounts receivable arise primarily from products sold and services provided in North America, Europe and Asia. The balance in accounts receivable represents the amount due from our domestic and foreign original equipment manufacturers, or OEM, customers, distributors and end users. We perform ongoing credit evaluations of our customers’ financial condition and continuously monitor collections and payments from our customers and maintain a provision for estimated credit losses based upon specific customer collection issues that have been identified. We accrue reserves against trade receivables for estimated losses that may result from a customer’s inability to pay. Amounts determined to be uncollectible are charged or written off against the reserve. To date, our historical write-offs of accounts receivable have been minimal. Our top ten customers combined accounted for approximately 61% and 62% of our total net revenue for each of the three months ended April 30, 2017 and 2016, respectively and 63% and 62% of our total net revenue for the nine months ended April 30, 2017 and 2016 respectively. Set forth in the table below are customers which individually accounted for 10% or more of our net revenue. Three Months Ended Nine Months Ended April 30, April 30, 2017 2016 2017 2016 Koninklijke Philips Electronics N.V., or Philips 14 % 14 % 14 % 13 % Siemens AG 11 % 11 % 12 % 13 % L-3 Communications Corporation, or L-3 11 % 10 % 10 % * Toshiba Corporation, or Toshiba * * * 11 % Note (*): Total net revenue was less than 10% in this period. The following table summarizes our customers with net accounts receivable balances greater than or equal to 10% of our total net accounts receivable balance: As of As of April 30, July 31, 2017 2016 L-3 12 % 17 % Philips 21 % 15 %

Inventory

Inventory	9 Months Ended
	Apr. 30, 2017
Inventory Disclosure [Abstract]
Inventory	4. Inventory The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows: As of As of April 30, July 31, (in millions) 2017 2016 Raw materials $ 68.4 $ 68.6 Work in process 47.5 45.6 Finished goods 28.4 31.3 Total inventory $ 144.3 $ 145.5

Intangible assets and goodwill

Intangible assets and goodwill	9 Months Ended
	Apr. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Intangible assets and goodwill	5. Intangible assets and goodwill Intangible assets Intangible assets include the value assigned to intellectual property and other technology, patents, customer contracts and relationships, and trade names. The estimated useful lives for all of these intangible assets, excluding a trade name determined to have an indefinite life, range between 1 to 14 years. Indefinite-lived intangible assets consist of trade names acquired in business combinations. The carrying values of our indefinite-lived intangible assets were $7.6 million at both nine months ended April 30, 2017 and July 31, 2016. Finite-lived intangible assets are summarized as follows: As of April 30, 2017 As of July 31, 2016 (in millions) Weighted Average Amortization Period Cost Accumulated Amortization/ Write-Offs Net Cost Accumulated Amortization Net Developed technologies 10 years $ 17.7 $ 13.9 $ 3.8 $ 29.9 $ 15.1 $ 14.8 Customer relationships 13 years 43.7 27.7 16.0 47.1 25.2 21.9 Trade names 3 years 0.9 0.9 - 1.9 1.0 0.9 Total finite-lived intangible assets $ 62.3 $ 42.5 $ 19.8 $ 78.9 $ 41.3 $ 37.6 Amortization expense related to acquired intangible assets was $1.9 million and $5.9 million for the three and nine months ended April 30, 2017, respectively. Amortization expense related to acquired intangible assets was $2.3 million and $6.3 for the three and nine months ended April 30, 2016, respectively. During the three months ended April 30, 2017, management noted impairment indicators related to the Oncura intangible assets which had a carrying value of $3.1 million. Oncura is part of our Ultrasound operating segment. as compared with our prior estimates resulting in the of $3.1 million, including a write-off of customer relationship of $2.4 million and a write-off of trade name of $0.7 million. more information on the acquisition of Oncura, please refer to Note 3. Business combination in our Annual Report on Form 10-K for fiscal year 2016, as filed with the SEC on September 27, 2016. During the three months ended April 30, 2017, management noted impairment indicators related to the PocketSonics intangible assets which had a carrying value of $8.1 million. PocketSonics is part of our Ultrasound operating segment. of $8.1 million, consisting of technology of $8.1 million. more information on the acquisition of PocketSonics, please refer to Note 3. Business combination in our Annual Report on Form 10-K for fiscal year 2016, as filed with the SEC on September 27, 2016. During the nine months ended April 30, 2017, intangible asset impairment charges were $11.9 million. The estimated future amortization expense related to intangible assets for the five succeeding fiscal years is expected to be as follows: Estimated Future Amortization (in millions) Expense Remaining 2017 $ 1.5 2018 $ 5.0 2019 $ 3.8 2020 $ 3.4 2021 $ 3.0 Thereafter $ 3.1 $ 19.8 Goodwill Analogic has goodwill balances of $2.3 million at April 30, 2017 and $73.9 million at July 31, 2016. We review periodically or more frequently if indicators are present or changes in circumstances suggest that it is more likely than not that impairment may exist Changes in the carrying amount of goodwill by reportable segments for the nine months ended April 30, 2017 are as follows: (in millions) Medical Imaging Ultrasound Security and Detection Total Goodwill Balance as of July 31, 2016 Goodwill $ 1.8 $ 71.6 $ 0.5 $ 73.9 Impairment losses - (71.6 ) - (71.6 ) Balance as of April 30, 2017 Goodwill 1.8 71.6 0.5 73.9 Accumulated impairment losses - (71.6 ) - (71.6 ) $ 1.8 $ - $ 0.5 $ 2.3 We have four reporting units with goodwill—Medical Imaging, Ultrasound, Oncura, and Security and Detection and three reportable segments—Medical Imaging, Ultrasound, and Security and Detection. We performed the annual impairment test for our goodwill and other intangible assets with indefinite lives as of December 31, 2016. We first assess qualitative factors to determine whether it is more likely than not that the fair value of a reporting unit is less than its carrying value and as a basis for determining whether it is necessary to perform the quantitative impairment test. Alternatively, we may elect to bypass the qualitative assessment and proceed to the two-step quantitative impairment test. If we choose to perform a qualitative assessment and determine it is more likely than not that the carrying value of the net assets is more than the fair value of the related operations, the two-step impairment process is then performed; otherwise, no further testing is required. Our quantitative impairment assessment considered both the market approach and income approach to calculate the fair value of the reporting unit, with different weights assigned to each. Under the market approach, the fair value of the reporting unit is based on trading multiples of a peer group of companies, which was determined based on an analysis of the selected guideline public companies’ business enterprise value (“BEV”) plus a control premium, which was determined based on an analysis of control premiums for recent relevant acquisitions. Under the income approach, the fair value of the reporting unit is based on the present value of estimated future cash flows, which are determined, based upon the Company’s most recent strategic operating plan and considering market participant assumptions. The income approach is dependent on a number of significant management assumptions including estimates of future revenues, costs and expenses, and a number of significant valuation inputs including discount rates, working capital rates and tax rates. During the second quarter of fiscal year 2017, for our Medical Imaging, Ultrasound, Oncura, and Security and Detection reporting units, we used the two-step quantitative impairment test. For the Security and Detection reporting unit, we performed the market approach and determined that the fair value of our Security and Detection reporting unit was in excess of its carrying value, and concluded that there was no impairment during the annual impairment test of goodwill and other intangible assets with indefinite lives as of December 31, 2016. For our Medical Imaging and Ultrasound reporting units, we used both the market approach and income approach and determined that there was no impairment of goodwill during the annual impairment test of goodwill and other intangible assets with indefinite lives as of December 31, 2016. For our Medical Imaging reporting unit, we determined that the estimated fair value of the Medical Imaging reporting unit substantially exceeds its carrying value. For our Ultrasound reporting unit, we determined that our Ultrasound reporting unit was at risk of failing the first step of the goodwill impairment test in future reporting periods due to forecast revisions and changes in strategy in our ultrasound business. For example, an increase in the discount rate applied to the Ultrasound cash flows of 300 basis points could result in a failure of Step 1 of the impairment test. Also, a decrease in the revenue compound annual growth rate within the Ultrasound cash flow forecast of 200 basis points could result in a failure of Step 1 of the impairment test. Our Ultrasound reporting unit had excess fair value over carrying value of approximately 25% as of our annual test date and held $55.1 million of allocated goodwill as of December 31, 2016. During the second quarter of fiscal year 2017, for our Oncura reporting unit, recent changes in our strategy caused us to decrease future forecasted revenues from our prior estimates. As a result, we determined that the associated goodwill was impaired and we recorded an estimated charge of $9.8 million in the second quarter of fiscal year 2017 during the annual impairment test of goodwill and other intangible assets with indefinite lives as of December 31, 2016. We recorded this amount in the asset impairment charges caption in our accompanying unaudited consolidated statements of operations. Intangibles-Goodwill and Other During the second quarter of fiscal year 2017, subsequent to the annual impairment test of goodwill and other intangible assets with indefinite lives as of December 31, 2016, we elected early adoption of ASU 2017-04 as of January 01, 2017, “Intangibles─Goodwill and Other (Topic 350): Simplifying the Test for Goodwill Impairment.” As a result, we removed Step 2 of the goodwill impairment test, which requires a hypothetical purchase price allocation. Goodwill impairment will now be the amount by which a reporting unit’s carrying value exceeds its fair value, not to exceed the carrying amount of goodwill. During the third quarter of fiscal year 2017, the Company noted impairment indicators related to our Ultrasound reporting unit. Additional delays related to the introduction and commercialization of our general imaging platform sold through our technology partner in general imaging caused the Company to reassess our revenue expectations for the product. This significant change, as well as a further reduction in revenue estimates for our fiscal 2017 impacted our overall revenue growth expectations in Ultrasound in future periods. of $55.1 million. During the third quarter of fiscal year 2017, for our Oncura reporting unit, as a result of decreased forecasted revenue as compared with our prior estimates, which was caused by the further disruption in our sales channel in our vet business, w e determined that the remaining goodwill was impaired and recorded a charge of $6.7 million in the third quarter of fiscal year 2017. We recorded this amount in the asset impairment charges caption in our accompanying unaudited consolidated statements of operations. As of April 30, 2017, the fair value of the contingent consideration obligation associated with the Oncura acquisition was taken to zero. We compared the fair value of a tradename that has an indefinite life using the relief from royalty approach to its carrying value as of December 31, 2016. The relief from royalty approach utilized an after-tax royalty rate and a discount rate. The after-tax royalty rate was determined based on royalty research and margin analysis, while the discount rate was determined after consideration of market rates of return on debt and equity capital, the weighted average return on invested capital, and the risk associated with achieving forecasted sales for the tradename. We determined that the fair value of the tradename was in excess of its carrying value. The current economic environment and the uncertainties regarding its impact on our business and our estimates for forecasted revenue and spending levels made for purposes of our goodwill and trade name impairment testing may not be accurate predictions of the future. If our assumptions regarding forecasted revenue or margin growth rates of each reporting unit and trade name are not achieved, we may be required to record an impairment charge for the goodwill and trade name in future periods, whether in connection with our next annual impairment testing in the second quarter of the fiscal year ending July 31, 2018, or prior to that if any such change constitutes a triggering event outside of the quarter from when the annual goodwill and trade name impairment test is performed. Changes in our forecasts, or decreases in the value of our common stock could cause book values of certain operations to exceed their fair values which may result in goodwill impairment charges in future periods. It is not possible at this time to determine if any such future impairment charge would result or, if it does, whether such charge would be material.

Fair value measurements

Fair value measurements	9 Months Ended
	Apr. 30, 2017
Fair Value Disclosures [Abstract]
Fair value measurements	6. Fair value measurements Fair value is defined as the exchange price that would be received for an asset or paid to transfer a liability (an exit price) in the principal or the most advantageous market for the asset transaction between market participants on the measurement date. Valuation techniques used to measure fair value must maximize the use of observable inputs and minimize the use of unobservable inputs. We use a fair value hierarchy based on three levels of inputs, of which the first two are considered observable and the last unobservable, that may be used to measure fair value: • Level 1 – Quoted prices in active markets for identical assets or liabilities. • Level 2 – Inputs other than Level 1 that are observable, either directly or indirectly, such as quoted prices for similar assets or liabilities, quoted prices in markets that are not active, or other inputs that are observable or can be corroborated by observable market data for substantially the full term of the assets or liabilities. • Level 3 – Unobservable inputs that are supported by little or no market activity and that are significant to the fair value of the assets or liabilities. The following tables provide the assets and liabilities carried at fair value and measured on a recurring basis at April 30, 2017 and July 31, 2016: Fair Value Measurements at April 30, 2017 (in millions) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash and cash equivalents $ 158.6 $ 158.6 $ - $ - Plan assets for deferred compensation 6.7 6.7 - - Total assets at fair value $ 165.3 $ 165.3 $ - $ - Liabilities Foreign currency forward contracts 0.5 - 0.5 - Total liabilities at fair value $ 0.5 $ - $ 0.5 $ - Fair Value Measurements at July 31, 2016 (in millions) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash and cash equivalents $ 118.7 $ 118.7 $ - $ - Plan assets for deferred compensation 5.9 5.9 - - Total assets at fair value $ 124.6 $ 124.6 $ - $ - Liabilities Contingent consideration $ 12.2 $ - $ - $ 12.2 Foreign currency forward contracts 0.3 - 0.3 - Total liabilities at fair value $ 12.5 $ - $ 0.3 $ 12.2 Assets held in the deferred compensation plan will be used to pay benefits under our non-qualified deferred compensation plan. The investments primarily consist of mutual funds which are publicly traded on stock exchanges. Accordingly, the fair value of these assets is categorized as Level 1 within the fair value hierarchy. The fair value of the liabilities arising from our foreign currency forward contracts is determined by valuation models based on market observable inputs, including forward and spot prices for currencies. Accordingly, the fair value of these liabilities is categorized as Level 2 within the fair value hierarchy. The fair value of our contingent consideration obligation is based on significant unobservable inputs, including management estimates and assumptions, and is measured based on the probability-weighted present value of the payments expected to be made. Accordingly, the fair value of this liability is categorized as Level 3 within the fair value hierarchy. The fair value of the contingent payments associated with the acquisition of PocketSonics, Inc., or PocketSonics, was calculated utilizing 100% probability for the earn out associated with the Section 510(k) clearance obtained from the Food and Drug Administration, or FDA, on April 9, 2014 and the first commercial shipment as defined in the purchase agreement, in the fiscal year ending July 31, 2016, or fiscal year 2016. Each quarter we revalue the contingent consideration obligations associated with the acquisition of PocketSonics to its then current fair value and record changes in the fair value to the Consolidated Statements of Operations. Changes in contingent consideration result from changes in the assumptions regarding probabilities of the estimated timing of launch, volume sales target, payments and the discount rate used to estimate the fair value of the liability. The assumptions used in estimating fair value require significant judgment. The use of different assumptions and judgments could result in a materially different estimate of fair value. There was no change in the fair value of our contingent consideration obligation during the three and nine months ended April 30, 2017. We paid out the $2.0 million contingent liability during the third quarter during fiscal year 2017. Please refer to Note 3. Business combination The fair value of the contingent payment obligation associated with the acquisition of Oncura was valued using a Monte Carlo simulation. The fair value of the contingent payment obligation of Oncura will be revalued each quarter to its then fair value and we will record changes in the fair value as contingent consideration expense within our Consolidated Statement of Operations within general and administrative operating expenses. Changes in contingent consideration expense result from changes in the assumptions regarding probabilities of the estimated future sales volume and gross margin targets and the discount rate used to estimate the fair value of the liability. The assumptions used in estimating the fair value require significant judgment. The use of different assumptions and judgments could result in a different estimate of fair value. There was a $2.1 million and $10.2 million decrease in the fair value of our contingent consideration obligation during the three and nine months ended April 30, 2017, due to revisions in our forecasted revenues of the Oncura business, which reduced the amount of contingent consideration we expect to pay. As of April 30, 2017, the fair value of the contingent consideration obligation associated with the Oncura acquisition was $0.0 million. For more information on the acquisition of Oncura, please refer to Note 3. Business combination

Derivative instruments

Derivative instruments	9 Months Ended
	Apr. 30, 2017
Derivative Instruments And Hedging Activities Disclosure [Abstract]
Derivative instruments	7. Derivative instruments Certain of our foreign operations have revenue and expenses transacted in currencies other than the U.S. dollar. In order to mitigate foreign currency exchange risk, we use forward contracts to lock in exchange rates associated with a portion of our forecasted international expenses. As of April 30, 2017, we have forward contracts outstanding with notional amounts totaling $11.6 million. These contracts are designated as cash flow hedges, and the unrealized loss of $0.3 million, net of tax, on these contracts are reported in Accumulated other comprehensive income as of April 30, 2017. Assets and liability derivatives designated as hedging instruments are presented in other assets and other liabilities, respectively, on our Consolidated Balance Sheets. At April 30, 2017 we had a derivative liability of $0.5 million included in other liabilities on our Consolidated Balance Sheet. As of July 31, 2016, we have forward contracts outstanding with notional amounts totaling $18.6 million. These contracts are designated as cash flow hedges, and the unrealized loss of $0.2 million, net of tax, on these contracts are reported in Accumulated other comprehensive income as of July 31, 2016. At July 31, 2016 we had a derivative liability of $0.3 million included in other liabilities on our Consolidated Balance Sheet. Realized gains and (losses) on the cash flow hedges are recognized in income in the period when the payment of expenses is recognized. During the three and nine months ended April 30, 2017 we recorded approximately $0.2 million and $0.5 million of realized loss, respectively, included in in our Consolidated Statements of Operations. During the three and nine months ended April 30, 2016 we recorded $0.2 million and $0.6 million of realized loss, respectively.

Common stock repurchases

Common stock repurchases	9 Months Ended
	Apr. 30, 2017
Text Block [Abstract]
Common stock repurchases	8. Common stock repurchases On May 26, 2016, our board of directors authorized the repurchase of up to $15.0 million of our common stock. After that authorization, we continued to repurchase stock with $1 million of unused capacity from the prior $30 million repurchase program, which was During the three and nine months ended April 30, 2017 , we repurchased and retired 13,578 shares of common stock under the June 2, 2014 repurchase program for $1.0 million at an average purchase price of $74.08 per share. The cumulative shares that were repurchased and retired under this program were 380,771 shares of common stock for $30.0 million at an average purchase price of $78.76 per share. The June 2, 2014 repurchase program is now complete. During the three and nine months ended April 30, 2017 , we repurchased and retired 8,090 shares of common stock under the May 26, 2016 repurchase program for $0.6 million at an average purchase price of $71.46 per share. The cumulative shares that were repurchased and retired under this program were 8,090 shares of common stock for $0.6 million at an average purchase price of $71.46 per share.

Accumulated other comprehensive

Accumulated other comprehensive income	9 Months Ended
	Apr. 30, 2017
Equity [Abstract]
Accumulated other comprehensive income	9. Accumulated other comprehensive income Components of comprehensive (loss) income include net income and certain transactions that have generally been reported in the Consolidated Statements of Changes in Stockholders’ Equity. Other comprehensive (loss) income consists of reported foreign currency translation gains and losses (net of taxes), actuarial gains and losses on pension plan assets (net of taxes), and changes in the unrealized value on foreign currency forward contracts (net of taxes). Deferred taxes are not provided on cumulative translation adjustments where we expect earnings of a foreign subsidiary to be indefinitely reinvested. The income tax effect of currency translation adjustments related to foreign subsidiaries that are not considered indefinitely reinvested is recorded as a component of deferred taxes with an offset to other comprehensive (loss) income. The following table summarizes components of Accumulated other comprehensive (loss) income for the nine months ended April 30, 2017: (in millions) Unrealized Gain on Foreign Currency Forward Contracts Unrealized Losses on Pension Plan Currency Translation Adjustment Accumulated Other Comprehensive Income Balance as of July 31, 2016 $ (0.2 ) $ (4.9 ) $ (3.4 ) $ (8.5 ) Pre-tax change before reclassification to earnings - 0.2 (2.3 ) (2.1 ) Amount reclassified to earnings (0.2 ) - - (0.2 ) Income tax benefit (provision) 0.1 - (0.2 ) (0.1 ) Balance as of April 30, 2017 $ (0.3 ) $ (4.7 ) $ (5.9 ) $ (10.9 ) The ineffective portion of the unrealized losses on foreign currency forward contracts and unrealized gains or losses on currency translation adjustment are included in other expense, net on our Consolidated Statements of Operations.

Share-based compensation

Share-based compensation	9 Months Ended
	Apr. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-based compensation	10. Share-based compensation The following table presents share-based compensation expense included in our Consolidated Statements of Operations: Three Months Ended Nine Months Ended April 30, April 30, (in millions) 2017 2016 2017 2016 Cost of product sales $ 0.1 $ 0.1 $ 0.3 $ 0.4 Cost of engineering sales - - 0.1 - Research and product development 0.4 0.6 1.2 1.8 Selling and marketing 0.2 0.4 1.1 1.1 General and administrative 1.5 1.8 3.7 3.8 Total share-based compensation expense before tax 2.2 2.9 6.4 7.1 Income tax effect (0.7 ) (1.0 ) (2.0 ) (2.2 ) Share-based compensation expense included in net income $ 1.5 $ 1.9 $ 4.4 $ 4.9 Stock options We estimate the fair value of stock options using the Black-Scholes valuation model. Key input assumptions used to estimate the fair value of stock options include the exercise price of the award, the expected option term, the expected volatility of our stock over the option’s expected term, the risk-free interest rate over the option’s expected term, and our expected annual dividend yield. Estimates of fair value are not intended to predict actual future events or the value ultimately realized by persons who receive equity awards. No stock options were granted during the three and nine months ended April 30, 2017 and April 30, 2016, respectively. The total intrinsic value of options exercised during the three and nine months ended April 30, 2017 was $0.0 million and $2.2 million, respectively. Restricted stock and restricted stock units We estimate the fair value of restricted stock units, or RSUs, that vest based on service conditions using the quoted closing price of our common stock on the date of grant. Share-based compensation expense is amortized over each award’s vesting period on a straight-line basis for all awards with service and performance conditions that vest at the end of the performance cycle, while the accelerated method applies to other awards with both service and performance conditions. For our non-GAAP earnings per share, or EPS awards, the compensation cost is amortized over the performance period on a straight-line basis, net of forfeitures, because such awards vest only at the end of the performance period. The compensation cost is based on the number of shares that are deemed probable of vesting at the end of the three-year performance cycle. This probability assessment is done each quarter and changes in estimates can result in significant expense fluctuations due to the cumulative catch-up adjustment. We estimate the fair value of the non-GAAP EPS awards using the quoted closing price of our common stock on the date of grant. For our relative total shareholder return, or TSR awards, which are based on market performance of our stock as compared to an industry peer group, the compensation cost is amortized over the performance period on a straight-line basis net of forfeitures, because the awards vest only at the end of the measurement period and the probability of actual shares expected to be earned is considered in the grant date valuation. As a result, the expense is not adjusted to reflect the actual shares earned. We estimate the fair value of the TSR awards using the Monte-Carlo simulation model. We granted 601 and 28,749 TSR awards and 594 and 62,626 non-GAAP EPS awards during the three and nine months ended April 30, 2017, respectively. We granted 0 and 24,821 TSR awards and 0 and 32,444 non-GAAP EPS awards during the three and nine months ended April 30, 2016, respectively. The fair value of our TSR performance-based awards at the date of grant was estimated using the Monte-Carlo simulation model with the following assumptions: Three Months Ended Nine Months Ended April 30, April 30, 2017 2016 2017 2016 Stock price (1) $ 73.60 $ - $ 89.88 $ 84.06 Expected volatility (2) 27.00 % 0.00 % 27.0 % 26.4 % Risk-free interest rate (3) 0.85 % 0.00 % 0.85 % 1.04 % Expected annual dividend yield (4) 0.00 % 0.00 % 0.00 % 0.00 % Weighted average grant date fair value of time-based restricted stock awards $ 78.22 $ 74.18 $ 88.16 $ 82.66 Weighted average grant date fair value of performance based restricted stock awards $ 73.60 $ - $ 86.88 $ 98.81 (1) The stock price is the closing price of our common stock on the date of grant. (2) The expected volatility for each grant is determined based on the historical volatility for the peer group companies and our common stock over a period equal to the remaining term of the performance period from the date of grant for all awards. (3) The risk-free interest rate is determined based on the yield of zero-coupon U.S. Treasury securities for a period that is commensurate with the performance period. (4) Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%. The total fair value of RSUs that vested during the three and nine months ended April 30, 2017 was $0.9 million and $4.1 million, respectively. The total fair value of RSUs that vested during the three and nine months ended April 30, 2016 was $0.9 million and $5.3 million, respectively. As of April 30, 2017, the unrecognized compensation cost, net of estimated forfeitures, related to unvested stock options and restricted stock was $9.2 million. This cost will be recognized over an estimated weighted average amortization period of 1.2 years and assumes target performance for the non-GAAP EPS awards.

Restructuring charges

Restructuring charges	9 Months Ended
	Apr. 30, 2017
Restructuring And Related Activities [Abstract]
Restructuring charges	11. Restructuring charges Fiscal Year 2017 Restructuring Plan On March 6, 2017, the Company announced a restructuring of its Ultrasound business designed to improve profitability and provide consistent long term growth. The Company intends to focus on its core markets of Urology and Surgery as well as specific areas of the Point of Care market where its products have a competitive advantage. The Company will consolidate the activities currently conducted in Vancouver, British Columbia with its existing operations in Copenhagen, Denmark and Peabody, Massachusetts and plans to exit the Vancouver facility by the end fiscal 2017. The Company intends to re-size its U.S. sales, global marketing as well as general and administration organizations in-line with its objectives. These activities will result in a workforce reduction of approximately 130 employees and is expected to be substantially completed by the end of fiscal 2017. The Company expects to incur restructuring related charges of up to $5.0 million in fiscal 2017. We incurred pre-tax charges of $2.1 and $2.5 million during the three and nine months ended April 30, 2017. Fiscal Year 2016 Restructuring Plan On September 16, 2015, the Company announced our fiscal year 2016 restructuring plan, or 2016 Restructuring Plan. This plan includes the transition of certain manufacturing activities from our Peabody, Massachusetts location to our existing facility in Shanghai, China, and a reduction in force in order to align our research and development investment with expected customer funding. We had pre-tax adjustment of approximately $0.0 million and $(0.1) million to restructuring during the three and nine months ended April 30, 2017. We incurred pre-tax charges of $1.8 million and $8.3 million during the three and nine months ended April 30, 2016, respectively, primarily relating to severance and personnel related costs for terminated employees. We expect that the 2016 Restructuring Plan will be substantially completed during the fourth quarter of fiscal year 2017. Current Period Activity The following table summarizes accrued restructuring activities for the three months ended April 30, 2017: Employee Severance Other and Restructuring (in millions) Benefits (A) Costs (A) Total Balance at January 31, 2017 $ 1.4 $ - $ 1.4 Restructuring charge 2.1 - 2.1 Adjustments - - - Cash payments (1.1 ) - (1.1 ) Balance at April 30, 2017 $ 2.4 $ - $ 2.4 (A) Restructuring charges in fiscal year 2017 includes $2.1 million with respect to the Fiscal Year 2017 Restructuring Plan. All other activity pertains to the Fiscal Year 2016 Restructuring Plan. The following table summarizes accrued restructuring activities for the nine months ended April 30, 2017: Employee Severance Other and Restructuring (in millions) Benefits (A) Costs (A) Total Balance at July 31, 2016 $ 5.2 $ - $ 5.2 Restructuring charge 2.5 - 2.5 Adjustments (0.1 ) - (0.1 ) Cash payments (5.2 ) - (5.2 ) Balance at April 30, 2017 $ 2.4 $ - $ 2.4 (A) Restructuring charges in fiscal year 2017 includes $2.4 million with respect to the Fiscal Year 2017 Restructuring Plan. All other activity pertains to the Fiscal Year 2016 Restructuring Plan. Restructuring and related charges, including actions associated with acquisitions, by segment are as follows: For Three Months Ended For Nine Months Ended April 30, April 30, (in millions) 2017 2016 2017 2016 Medical Imaging $ 0.2 $ 1.1 $ 0.4 $ 5.1 Ultrasound 1.8 0.4 $ 1.9 1.7 Security and Detection 0.1 0.3 $ 0.1 1.5 Total restructuring and related charges $ 2.1 $ 1.8 $ 2.4 $ 8.3 Accrued restructuring charges are classified on the Consolidated Balance Sheets in the Current Liabilities section.

Net income per common share

Net income per common share	9 Months Ended
	Apr. 30, 2017
Earnings Per Share [Abstract]
Net income per common share	12. Net income per common share Basic net income per share is computed using the weighted average number of common shares outstanding during the period. Diluted net income per share is computed using the sum of the weighted average number of common shares outstanding during the period and, if dilutive, the weighted average number of potential shares of common stock, including unvested restricted stock and the assumed exercise of stock options using the treasury stock method. Basic and diluted net income per share are calculated as follows: Three Months Ended Nine Months Ended April 30, April 30, (in millions, except per share data and share data in thousands) 2017 2016 2017 2016 Net (loss) income $ (59.7 ) $ 5.0 $ (49.6 ) $ 3.4 Weighted average number of common shares outstanding-basic 12,486 12,392 12,457 12,412 Effect of dilutive securities: - - - - Stock options and restricted stock units - 161 - 211 Weighted average number of common shares outstanding-diluted 12,486 12,553 12,457 12,623 Basic net (loss) income per share $ (4.78 ) $ 0.40 $ (3.98 ) $ 0.27 Diluted net (loss) income per share $ (4.78 ) $ 0.40 $ (3.98 ) $ 0.27 Anti-dilutive shares related to outstanding stock options and unvested restricted stock (A) 242 87 228 5 (A) These shares related to outstanding stock options and unvested restricted stock were not included in our calculations of diluted earnings per share, as the effect of including them would be anti-dilutive.

Income taxes

Income taxes	9 Months Ended
	Apr. 30, 2017
Income Tax Disclosure [Abstract]
Income taxes	13. Income taxes The following table presents the provision for income taxes and our effective tax rate for the three and nine months ended April 30, 2017 and 2016: Three Months Ended Nine Months Ended April 30, April 30, (in millions except percentages) 2017 2016 2017 2016 (Benefit)/provision for income taxes $ (4.9 ) $ 1.7 $ (1.9 ) $ 2.9 Effective tax rate 8 % 26 % 4 % 46 % The effective income tax rate on operations is based upon the estimated income for the year, including the goodwill and intangibles impairments discussed elsewhere, the composition of the income in different countries, and adjustments, if any, in the applicable quarterly periods for the potential tax consequences, benefits, resolutions of tax audits or other tax contingencies. Our effective tax rate for the three months ended April 30, 2017 is lower than the statutory rate of 35% primarily due to operating losses generated in the United States, tax credits in the United States and Canada in spite of operating losses, and non-recurring discrete tax items. Our effective tax rate for the nine months ended April 30, 2017 is lower than the statutory rate of 35% primarily due to losses generated in the US by impairment charges, income generated outside the United States in countries with lower tax rates, tax credits in the United States and Canada, and discrete tax benefits. The tax provision for the three and nine months ended April 30, 2017 includes discrete tax benefits totaling $0.5 million and $0.9 million, respectively. Our effective tax rate for the three and nine months ended April 30, 2016 differs from the statutory rate of 35% primarily due to non-deductible and reserve items related to the BK Medical matter and expiration of statute of limitations for the income tax returns in the United States for fiscal year ended July 31, 2012. Additional impacts to our rate resulted from income generated outside the United States in countries with lower tax rates and from tax Credits in the United States and Canada. The tax provision for the three and nine months ended April 30, 2016 includes discrete tax benefits totaling $(0.2) million and $1.1 million, respectively. For more information on the BK Medical matter, please refer to Note 11. Commitments, guarantees and contingencies in our Annual Report on Form 10-K for fiscal year 2016, as filed with the SEC on September 27, 2016. We are subject to U.S. Federal income tax as well as the income tax of multiple state and foreign jurisdictions. As of April 30, 2017, we have concluded all U.S. Federal income tax matters through the year ended July 31, 2012. We accrue interest and, if applicable, penalties for any uncertain tax positions. This interest and penalty expense is treated as a component of income tax expense. At April 30, 2017 and July 31, 2016, we had approximately $0.3 million and $0.4 million accrued for interest and penalties on unrecognized tax benefits. At April 30, 2017, we had $6.9 million of unrecognized tax benefits for uncertain tax positions and $0.3 million of related accrued interest and penalties. We are unable to reasonably estimate the amount and period in which these liabilities might be paid. We do not provide for U.S. Federal income taxes on undistributed earnings of consolidated foreign subsidiaries, as such earnings are intended to be indefinitely reinvested in those operations. Determination of the potential deferred income tax liability on these undistributed earnings is not practicable because such liability, if any, is dependent on circumstances that exist if and when remittance occurs. The circumstances that would affect the calculations would be the source location and amount of the distribution, the underlying tax rate already paid on the earnings, foreign withholding taxes and the opportunity to use foreign tax credits.

Segment information

Segment information	9 Months Ended
	Apr. 30, 2017
Segment Reporting [Abstract]
Segment information	14. Segment information Our business is strategically aligned into three segments: Medical Imaging, Ultrasound, and Security and Detection. Our business segments are described as follows: • Medical Imaging primarily includes systems and subsystems for CT and MRI medical imaging equipment as well as state-of-the-art, selenium-based detectors for screening of breast cancer and other diagnostic applications in mammography. • Ultrasound includes ultrasound systems and transducers primarily in the urology, surgery, and point-of-care markets. • Security and Detection includes advanced threat detecting CT systems utilizing our expertise in advanced imaging technology, primarily used in the checked baggage screening at airports worldwide. The tables below present information about our reportable segments: Three Months Ended Nine Months Ended April 30, April 30, (in millions) 2017 2016 2017 2016 Product revenue: Medical Imaging $ 68.2 $ 71.9 $ 205.9 $ 208.7 Ultrasound 34.8 36.8 110.7 115.9 Security and Detection 17.8 17.6 54.8 41.8 Total product revenue $ 120.8 $ 126.3 $ 371.4 $ 366.4 Engineering revenue: Medical Imaging $ 1.3 $ 0.9 $ 3.1 $ 2.6 Ultrasound - 0.8 0.2 1.7 Security and Detection 0.1 (0.1 ) 0.1 0.1 Total engineering revenue $ 1.4 $ 1.6 $ 3.4 $ 4.4 Net revenue: Medical Imaging $ 69.5 $ 72.9 $ 209.0 $ 211.3 Ultrasound 34.8 37.6 110.9 117.6 Security and Detection 17.9 17.5 54.9 41.9 Total net revenue $ 122.2 $ 128.0 $ 374.8 $ 370.8 Income (loss) from operations: Medical Imaging (A) $ 12.2 $ 10.2 $ 31.3 $ 28.2 Ultrasound (B) (79.3 ) (5.0 ) (89.7 ) (19.5 ) Security and Detection (C ) 2.5 2.4 7.2 2.4 Total (loss) income from operations (64.6 ) 7.6 (51.2 ) 11.1 Total other income (loss), net 0.10 (0.9 ) (0.4 ) (4.9 ) (Loss) income before income taxes $ (64.5 ) $ 6.7 $ (51.6 ) $ 6.2 As of As of April 30, July 31, (in millions) 2017 2016 Identifiable total assets by segment: Medical Imaging $ 182.8 $ 191.1 Ultrasound 146.8 152.5 Security and Detection 42.6 49.8 Total reportable segment assets 372.2 393.4 Corporate assets (D) 193.1 165.6 Total identifiable assets $ 565.3 $ 559.0 (A) Includes restructuring charges of $0.2 million and $1.1 million for three months ended April 30, 2017 and April 30, 2016, respectively and $0.4 million and $5.1 million for nine months ended April 30, 2017 and April 30, 2016. (B) Includes restructuring charges of $1.8 million and $0.4 million for three months ended April 30, 2017 and April 30, 2016, respectively and $1.9 million and $1.7 million for nine months ended April 30, 2017 and April 30, 2016. Includes contingent consideration charges of $(2.1) million and $(10.2) million related to Oncura for three and nine months ended April 30, 2017, respectively. Includes asset impairment charges of $3.1 million related to Oncura intangible assets for three and nine months ended April 30, 2017. Includes asset impairment charges of $8.1 million related to PocketSonics intangible assets for three and nine months ended April 30, 2017. Includes goodwill impairment charges of $6.7 million and $16.5 million related to Oncura reporting unit for three and nine months ended April 30, 2017. Includes goodwill impairment charges of $55.1 million related to Ultrasound reporting unit for three and nine months ended April 30, 2017. Includes charges for the BK Medical matter of $0.0 million and $10.1 million for three and nine months ended April 30, 2016 . (C) Includes restructuring charges of $0.1 million and $0.3 million for three months ended April 30, 2017 and April 30, 2016, respectively and $0.1 million and $1.5 million for nine months ended April 30, 2017 and April 30, 2016. Includes asset impairment charges of $0.0 million and $0.6 million related to Pathfinder for three and nine months ended April 30, 2017. (D) Includes cash and cash equivalents of $144.9 million and $97.3 million as of April 30, 2017 and July 31, 2016, respectively.

Guarantees, commitments and con

Guarantees, commitments and contingencies	9 Months Ended
	Apr. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Guarantees, commitments and contingencies	15. Guarantees, commitments and contingencies Guarantees and Indemnification Obligations Our standard OEM and supply agreements entered in the ordinary course of business typically contain an indemnification provision pursuant to which we indemnify, hold harmless, and agree to reimburse the indemnified party for losses suffered or incurred by the indemnified party in connection with any U.S. patent or any copyright or other intellectual property infringement claim by any third party with respect to our products. Such provisions generally survive termination or expiration of the agreements. The potential amount of future payments we could be required to make under these indemnification provisions is, in some instances, unlimited. Our costs to defend lawsuits or settle claims related to these indemnification agreements have been insignificant to date. As a result, we believe that our estimated exposure on these agreements is currently minimal. Accordingly, we have no liabilities recorded for these agreements as of April 30, 2017. Generally, we warrant that our products will perform in all material respects in accordance with our standard published specifications in effect at the time of delivery of the products to the customer for a period ranging from 12 to 60 months from the date of delivery. We provide for the estimated cost of product and service warranties based on specific warranty claims, claim history, and engineering estimates, where applicable. The following table presents our product warranty liability as of April 30, 2017: As of April 30, (in millions) 2017 Beginning balance $ 6.3 Provision 0.8 Settlements made in cash or in kind during the period (0.9 ) Ending balance $ 6.2 At April 30, 2017 and July 31, 2016, we had deferred revenue for extended product warranty contracts of $0.3 million and $0.2 million, respectively. Revolving Credit Agreements On November 23, 2015, we entered into a five-year revolving credit agreement, or Credit Agreement, with the financial institutions identified therein as lenders, which included JPMorgan Chase Bank, N.A., TD Bank, N.A., Wells Fargo Bank, N.A., HSBC Bank, N.A., and People’s United Bank, N.A. The Credit Agreement provides $100.0 million in available credit and expires on November 23, 2020, when all outstanding borrowings must be paid in full. The credit facility does not require amortization of principal and may be reduced before maturity in whole or in part at our option without penalty. Upon entry into the Credit Agreement, we terminated without penalty a $100.0 million five-year, revolving credit agreement entered into on October 11, 2011 and previously paid in full in accordance with its terms. Borrowings under the Credit Agreement may be used for general corporate purposes, including permitted acquisitions. The amount of available credit can be increased under specified circumstances up to $200.0 million in aggregate. We are the sole borrower under the Credit Agreement. The obligations under the credit facility are guaranteed as required to be by our material domestic subsidiaries as designated by us from time to time or as required under the Credit Agreement. There are no pledges of the capital stock or assets of our international subsidiaries. Interest rates on borrowings outstanding under the credit facility range from 1.25% to 1.75% above the LIBOR rate, or, at our option range from 0.00% to 1.00% above a defined base rate, the amount in each case varying based upon our leverage ratio. A quarterly commitment fee ranging from 0.20% to 0.35% per annum is applicable on the undrawn portion of the credit facility, based upon our leverage ratio. The Credit Agreement limits our and our subsidiaries’ ability to, among other things: incur additional indebtedness; incur liens or guarantee obligations; pay dividends or make other distributions; make investments; dispose of assets; and engage in transactions with affiliates except on an arms-length basis. In addition, the Credit Agreement requires us to maintain the following financial ratios: • A leverage ratio, defined as consolidated funded indebtedness to consolidated trailing four quarters earnings before interest, taxes, depreciation and amortization, or EBITDA, with the adjustments as stipulated in the Credit Agreement, of no greater than 2.75:1.00 (with a temporary step-up in the event of certain acquisitions); and • An interest coverage ratio, defined as the ratio of consolidated trailing four quarters adjusted EBITDA to consolidated interest charges of no less than 3.00:1.00 at any time. As of April 30, 2017, our leverage ratio was 0.004:1.00 and our interest coverage ratio was not applicable as we had no attributable interest expense. As of April 30, 2017, we were in full compliance with all financial and operating covenants contained in the Credit Agreement. Any failure to comply with the financial or operating covenants of the credit facility would prevent us from being able to borrow and would also constitute a default, permitting the lenders to, among other things, accelerate repayment of outstanding borrowings, including all accrued interest and fees, and to terminate the credit facility. A change in control, as defined in the Credit Agreement, would also constitute an event of default, permitting the lenders to accelerate repayment and terminate the Credit Agreement. In connection with entering into the Credit Agreement, we incurred approximately $0.5 million of transactions costs, which are being amortized over the five-year life of the credit facility. As of April 30, 2017 and July 31, 2016, we had approximately $1.2 million in other revolving credit facilities with banks available for direct borrowings. We did not have any borrowing outstanding under any of our credit facilities at April 30, 2017 and July 31, 2016, respectively. Legal Claims We are subject to litigation, claims, investigations and audits arising from time to time in the ordinary course of our business. Although legal proceedings are inherently unpredictable, we believe that we have valid defenses with respect to those matters currently pending against us and intend to defend ourselves vigorously. The outcome of these matters, individually and in the aggregate, is not expected to have a material impact on our cash flows, results of operations, or financial position. We record losses when estimable and probable in accordance with U.S. GAAP. On January 3, 2017, the Company's subsidiary Ultrasonix Medical Corporation ("UMC") received a notice of civil claim as a defendant. The lawsuit relates to the lease of a corporate office in Burnaby, British Columbia, of which UMC never took possession. The lawsuit claims that UMC is indebted to the landlord for unpaid and accelerated rent in an amount of approximately CAD 1.0 million, plus costs, plus interest on unpaid rent commencing in April 2014. During the third quarter of fiscal 2017 ended April 30, 2017, the Company filed a response in which it contests both liability and the extent of damages. During the three and nine months ended April 30, 2017, we accrued a $0.4 million charge in connection with this matter. The Company’s reasonable estimate of this liability is a range between $0.4 million and $0.7 million, with no amount within that range a better estimate than any other amount; accordingly, $0.4 million was accrued.

Subsequent events

Subsequent events	9 Months Ended
	Apr. 30, 2017
Subsequent Events [Abstract]
Subsequent events	16. Subsequent events We declared a dividend of $0.10 per share of common stock on June 1, 2017, which will be paid on June 30, 2017 to stockholders of record on June 16, 2017.

Recent accounting pronounceme23

Recent accounting pronouncements (Policies)	9 Months Ended
	Apr. 30, 2017
Accounting Changes And Error Corrections [Abstract]
Recent accounting pronouncements	Accounting pronouncements issued and recently adopted None. Accounting pronouncements issued and not yet effective Clarifying the Definition of a Business In January 2017, the FASB issued ASU No. 2017-01, “Business Combinations (Topic 805): Clarifying the Definition of a Business.” The amendments provide the requirements needed for a set to be a business and establish a practical way to determine when a set is not a business. To be considered a business, an acquisition would have to include an input and a substantive process that together significantly contribute to the ability to create outputs. An output is the result of inputs and substantive processes that provide goods or services to customers, other revenue, or investment income, such as dividends and interest. The amendments narrow the definition of outputs and align it with how outputs are described in Topic 606 “Revenue from Contracts with Customers”. The amendments are effective for annual periods beginning after December 15, 2017, including interim periods within those periods. Early adoption is permitted. The standard will be effective for us in fiscal years beginning August 1, 2018. We are currently evaluating the impact of the adoption of this update on our consolidated financial statements. Classification of Certain Cash Receipts and Cash Payments In August 2016, the FASB issued ASU No. 2016-15, “ Statement of Cash Flows (Topic 230).” The amendments provide guidance on the eight specific cash flow statement presentation and classification issues as follows: (1) debt prepayment or debt extinguishment costs; (2) settlement of zero-coupon debt instruments or other debt instruments with coupon interest rates that are insignificant in relation to the effective interest rate of the borrowing; (3) contingent consideration payments made after a business combination; (4) proceeds from the settlement of insurance claims; (5) proceeds from the settlement of corporate-owned life insurance policies, including bank-owned life insurance policies; (6) distributions received from equity method investees; (7) beneficial interests in securitization transactions; and (8) separately identifiable cash flows and application of the predominance principle. The amendments are effective for fiscal years beginning after December 15, 2017, and interim periods within those fiscal years. Early adoption is permitted. The standard will be effective for us in the first quarter of our fiscal year ending July 31, 2019. We are currently evaluating the impact of the adoption of this update on our consolidated financial statements. Improvements to employee share-based payment accounting In March 2016, the FASB issued ASU No. 2016-09, “Improvements to Employee Share-Based Payment Accounting,” which amends ASC 718, “Stock Based Compensation.” The amendments require that all excess tax benefits be recorded as an income tax benefit or expense in the income statement and be classified as an operating activity in the statement of cash flows. Entities may also elect to estimate the amount of forfeitures or recognize them as they occur. The amendments are effective for fiscal years, and interim periods within those years, beginning after December 15, 2016. The standard will be effective for us in the first quarter of our fiscal year ending July 31, 2018 and early adoption is permitted. We are currently evaluating the impact of the adoption of this update on our consolidated financial statements. Leases In February 2016, the FASB issued ASU No. 2016-02, “Leases (Topic 842)”. The standard requires lessees to recognize assets and liabilities for most leases on the balance sheet. For income statement purposes, the standard requires leases to be classified as either operating or finance. The standard is effective for annual and interim periods beginning after December 15, 2018. Early adoption is permitted. The standard will be effective for us in the first quarter of our fiscal year ending July 31, 2020. Adoption requires application of the new guidance for all periods presented. We are currently evaluating the impact of the adoption of this standard on our consolidated financial statements. Revenue from contracts with customers In May 2014, the FASB issued ASU No. 2014-09, “Revenue from Contracts with Customers (Topic 606)”. This update affects any entity that either enters into contracts with customers to transfer goods or services or enters into contracts for the transfer of nonfinancial assets. This update will supersede existing revenue recognition requirements and most industry-specific guidance. This update also supersedes some cost guidance, including revenue recognition guidance for construction-type and production-type contracts. The update’s core principle is that a company will recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the company expects to be entitled in exchange for those goods or services. In doing so, companies will need to use more judgment and make more estimates than under today’s guidance. These may include identifying performance obligations in the contract, estimating the amount of variable consideration to include in the transaction price and allocating the transaction price to each separate performance obligation. This update should be applied either on a retrospective or modified retrospective basis. This update was originally effective for us in the first quarter of our fiscal year ending July 31, 2018. Early adoption was not permitted. In August 2015, the FASB approved a one year delay of the effective date of the new revenue standard for public entities. Therefore, this update would be effective for us in the first quarter of our fiscal year ending July 31, 2019. The standard permits entities to early adopt, but only as of the original effective date (i.e. one year earlier). We are expected to adopt the new standard in the first quarter of our fiscal year 2019 effective August 01, 2018. We are still in the early stage of assessing the adoption method and analyzing the impact of the adoption of this update on our consolidated financial statements. We are unable to quantify the impact at this time. We established a project plan and an implementation team. The implementation team continues to apprise both management and the Audit Committee of project status on a recurring basis.

Accounts receivable, net (Table

Accounts receivable, net (Tables)	9 Months Ended
	Apr. 30, 2017
Risks And Uncertainties [Abstract]
Percentage of Net Product and Engineering Revenue from Major Customers	Set forth in the table below are customers which individually accounted for 10% or more of our net revenue. Three Months Ended Nine Months Ended April 30, April 30, 2017 2016 2017 2016 Koninklijke Philips Electronics N.V., or Philips 14 % 14 % 14 % 13 % Siemens AG 11 % 11 % 12 % 13 % L-3 Communications Corporation, or L-3 11 % 10 % 10 % * Toshiba Corporation, or Toshiba * * * 11 %
Summary of Net Accounts Receivable Due from Customers With Net Accounts Receivable Balance Greater than or Equal to 10% of Net Account Receivable Balance	The following table summarizes our customers with net accounts receivable balances greater than or equal to 10% of our total net accounts receivable balance: As of As of April 30, July 31, 2017 2016 L-3 12 % 17 % Philips 21 % 15 %

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Apr. 30, 2017
Inventory Disclosure [Abstract]
Components of inventory, net	The components of inventory, net of allowance for obsolete, unmarketable or slow-moving inventories, are summarized as follows: As of As of April 30, July 31, (in millions) 2017 2016 Raw materials $ 68.4 $ 68.6 Work in process 47.5 45.6 Finished goods 28.4 31.3 Total inventory $ 144.3 $ 145.5

Intangible assets and goodwill

Intangible assets and goodwill (Tables)	9 Months Ended
	Apr. 30, 2017
Goodwill And Intangible Assets Disclosure [Abstract]
Finite-Lived Intangible Assets	Finite-lived intangible assets are summarized as follows: As of April 30, 2017 As of July 31, 2016 (in millions) Weighted Average Amortization Period Cost Accumulated Amortization/ Write-Offs Net Cost Accumulated Amortization Net Developed technologies 10 years $ 17.7 $ 13.9 $ 3.8 $ 29.9 $ 15.1 $ 14.8 Customer relationships 13 years 43.7 27.7 16.0 47.1 25.2 21.9 Trade names 3 years 0.9 0.9 - 1.9 1.0 0.9 Total finite-lived intangible assets $ 62.3 $ 42.5 $ 19.8 $ 78.9 $ 41.3 $ 37.6
Estimated Future Amortization Expense Related to Intangible Assets	The estimated future amortization expense related to intangible assets for the five succeeding fiscal years is expected to be as follows: Estimated Future Amortization (in millions) Expense Remaining 2017 $ 1.5 2018 $ 5.0 2019 $ 3.8 2020 $ 3.4 2021 $ 3.0 Thereafter $ 3.1 $ 19.8
Changes in the Carrying Amount of Goodwill by Reportable Segments	Changes in the carrying amount of goodwill by reportable segments for the nine months ended April 30, 2017 are as follows: (in millions) Medical Imaging Ultrasound Security and Detection Total Goodwill Balance as of July 31, 2016 Goodwill $ 1.8 $ 71.6 $ 0.5 $ 73.9 Impairment losses - (71.6 ) - (71.6 ) Balance as of April 30, 2017 Goodwill 1.8 71.6 0.5 73.9 Accumulated impairment losses - (71.6 ) - (71.6 ) $ 1.8 $ - $ 0.5 $ 2.3

Fair value measurements (Tables

Fair value measurements (Tables)	9 Months Ended
	Apr. 30, 2017
Fair Value Disclosures [Abstract]
Assets and Liabilities Carried at Fair Value and Measured on Recurring Basis	The following tables provide the assets and liabilities carried at fair value and measured on a recurring basis at April 30, 2017 and July 31, 2016: Fair Value Measurements at April 30, 2017 (in millions) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash and cash equivalents $ 158.6 $ 158.6 $ - $ - Plan assets for deferred compensation 6.7 6.7 - - Total assets at fair value $ 165.3 $ 165.3 $ - $ - Liabilities Foreign currency forward contracts 0.5 - 0.5 - Total liabilities at fair value $ 0.5 $ - $ 0.5 $ - Fair Value Measurements at July 31, 2016 (in millions) Total Quoted Prices in Active Markets for Identical Assets (Level 1) Significant Other Observable Inputs (Level 2) Significant Unobservable Inputs (Level 3) Assets Cash and cash equivalents $ 118.7 $ 118.7 $ - $ - Plan assets for deferred compensation 5.9 5.9 - - Total assets at fair value $ 124.6 $ 124.6 $ - $ - Liabilities Contingent consideration $ 12.2 $ - $ - $ 12.2 Foreign currency forward contracts 0.3 - 0.3 - Total liabilities at fair value $ 12.5 $ - $ 0.3 $ 12.2

Accumulated other comprehensi28

Accumulated other comprehensive income (Tables)	9 Months Ended
	Apr. 30, 2017
Equity [Abstract]
Changes in Accumulated Other Comprehensive (Loss) Income	The following table summarizes components of Accumulated other comprehensive (loss) income for the nine months ended April 30, 2017: (in millions) Unrealized Gain on Foreign Currency Forward Contracts Unrealized Losses on Pension Plan Currency Translation Adjustment Accumulated Other Comprehensive Income Balance as of July 31, 2016 $ (0.2 ) $ (4.9 ) $ (3.4 ) $ (8.5 ) Pre-tax change before reclassification to earnings - 0.2 (2.3 ) (2.1 ) Amount reclassified to earnings (0.2 ) - - (0.2 ) Income tax benefit (provision) 0.1 - (0.2 ) (0.1 ) Balance as of April 30, 2017 $ (0.3 ) $ (4.7 ) $ (5.9 ) $ (10.9 )

Share-based compensation (Table

Share-based compensation (Tables)	9 Months Ended
	Apr. 30, 2017
Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]
Share-Based Compensation Expense	The following table presents share-based compensation expense included in our Consolidated Statements of Operations: Three Months Ended Nine Months Ended April 30, April 30, (in millions) 2017 2016 2017 2016 Cost of product sales $ 0.1 $ 0.1 $ 0.3 $ 0.4 Cost of engineering sales - - 0.1 - Research and product development 0.4 0.6 1.2 1.8 Selling and marketing 0.2 0.4 1.1 1.1 General and administrative 1.5 1.8 3.7 3.8 Total share-based compensation expense before tax 2.2 2.9 6.4 7.1 Income tax effect (0.7 ) (1.0 ) (2.0 ) (2.2 ) Share-based compensation expense included in net income $ 1.5 $ 1.9 $ 4.4 $ 4.9
Fair Value of TSR Performance-Based Awards Grant Assumptions	The fair value of our TSR performance-based awards at the date of grant was estimated using the Monte-Carlo simulation model with the following assumptions: Three Months Ended Nine Months Ended April 30, April 30, 2017 2016 2017 2016 Stock price (1) $ 73.60 $ - $ 89.88 $ 84.06 Expected volatility (2) 27.00 % 0.00 % 27.0 % 26.4 % Risk-free interest rate (3) 0.85 % 0.00 % 0.85 % 1.04 % Expected annual dividend yield (4) 0.00 % 0.00 % 0.00 % 0.00 % Weighted average grant date fair value of time-based restricted stock awards $ 78.22 $ 74.18 $ 88.16 $ 82.66 Weighted average grant date fair value of performance based restricted stock awards $ 73.60 $ - $ 86.88 $ 98.81 (1) The stock price is the closing price of our common stock on the date of grant. (2) The expected volatility for each grant is determined based on the historical volatility for the peer group companies and our common stock over a period equal to the remaining term of the performance period from the date of grant for all awards. (3) The risk-free interest rate is determined based on the yield of zero-coupon U.S. Treasury securities for a period that is commensurate with the performance period. (4) Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.

Restructuring charges (Tables)

Restructuring charges (Tables)	9 Months Ended
	Apr. 30, 2017
Summary of Charges Related to Accrued Restructuring Activities	The following table summarizes accrued restructuring activities for the three months ended April 30, 2017: Employee Severance Other and Restructuring (in millions) Benefits (A) Costs (A) Total Balance at January 31, 2017 $ 1.4 $ - $ 1.4 Restructuring charge 2.1 - 2.1 Adjustments - - - Cash payments (1.1 ) - (1.1 ) Balance at April 30, 2017 $ 2.4 $ - $ 2.4 (A) Restructuring charges in fiscal year 2017 includes $2.1 million with respect to the Fiscal Year 2017 Restructuring Plan. All other activity pertains to the Fiscal Year 2016 Restructuring Plan. The following table summarizes accrued restructuring activities for the nine months ended April 30, 2017: Employee Severance Other and Restructuring (in millions) Benefits (A) Costs (A) Total Balance at July 31, 2016 $ 5.2 $ - $ 5.2 Restructuring charge 2.5 - 2.5 Adjustments (0.1 ) - (0.1 ) Cash payments (5.2 ) - (5.2 ) Balance at April 30, 2017 $ 2.4 $ - $ 2.4 (A) Restructuring charges in fiscal year 2017 includes $2.4 million with respect to the Fiscal Year 2017 Restructuring Plan. All other activity pertains to the Fiscal Year 2016 Restructuring Plan.
Restructuring and related charges, including actions associated with acquisitions
Restructuring and Related Charges by Segment	Restructuring and related charges, including actions associated with acquisitions, by segment are as follows: For Three Months Ended For Nine Months Ended April 30, April 30, (in millions) 2017 2016 2017 2016 Medical Imaging $ 0.2 $ 1.1 $ 0.4 $ 5.1 Ultrasound 1.8 0.4 $ 1.9 1.7 Security and Detection 0.1 0.3 $ 0.1 1.5 Total restructuring and related charges $ 2.1 $ 1.8 $ 2.4 $ 8.3

Net income per common share (Ta

Net income per common share (Tables)	9 Months Ended
	Apr. 30, 2017
Earnings Per Share [Abstract]
Computation of Basic and Diluted Net Income Per Share	Basic and diluted net income per share are calculated as follows: Three Months Ended Nine Months Ended April 30, April 30, (in millions, except per share data and share data in thousands) 2017 2016 2017 2016 Net (loss) income $ (59.7 ) $ 5.0 $ (49.6 ) $ 3.4 Weighted average number of common shares outstanding-basic 12,486 12,392 12,457 12,412 Effect of dilutive securities: - - - - Stock options and restricted stock units - 161 - 211 Weighted average number of common shares outstanding-diluted 12,486 12,553 12,457 12,623 Basic net (loss) income per share $ (4.78 ) $ 0.40 $ (3.98 ) $ 0.27 Diluted net (loss) income per share $ (4.78 ) $ 0.40 $ (3.98 ) $ 0.27 Anti-dilutive shares related to outstanding stock options and unvested restricted stock (A) 242 87 228 5 (A) These shares related to outstanding stock options and unvested restricted stock were not included in our calculations of diluted earnings per share, as the effect of including them would be anti-dilutive.

Income taxes (Tables)

Income taxes (Tables)	9 Months Ended
	Apr. 30, 2017
Income Tax Disclosure [Abstract]
Provision for Income Taxes and Effective Tax Rate	The following table presents the provision for income taxes and our effective tax rate for the three and nine months ended April 30, 2017 and 2016: Three Months Ended Nine Months Ended April 30, April 30, (in millions except percentages) 2017 2016 2017 2016 (Benefit)/provision for income taxes $ (4.9 ) $ 1.7 $ (1.9 ) $ 2.9 Effective tax rate 8 % 26 % 4 % 46 %

Segment information (Tables)

Segment information (Tables)	9 Months Ended
	Apr. 30, 2017
Segment Reporting [Abstract]
Reportable Segment Information	The tables below present information about our reportable segments: Three Months Ended Nine Months Ended April 30, April 30, (in millions) 2017 2016 2017 2016 Product revenue: Medical Imaging $ 68.2 $ 71.9 $ 205.9 $ 208.7 Ultrasound 34.8 36.8 110.7 115.9 Security and Detection 17.8 17.6 54.8 41.8 Total product revenue $ 120.8 $ 126.3 $ 371.4 $ 366.4 Engineering revenue: Medical Imaging $ 1.3 $ 0.9 $ 3.1 $ 2.6 Ultrasound - 0.8 0.2 1.7 Security and Detection 0.1 (0.1 ) 0.1 0.1 Total engineering revenue $ 1.4 $ 1.6 $ 3.4 $ 4.4 Net revenue: Medical Imaging $ 69.5 $ 72.9 $ 209.0 $ 211.3 Ultrasound 34.8 37.6 110.9 117.6 Security and Detection 17.9 17.5 54.9 41.9 Total net revenue $ 122.2 $ 128.0 $ 374.8 $ 370.8 Income (loss) from operations: Medical Imaging (A) $ 12.2 $ 10.2 $ 31.3 $ 28.2 Ultrasound (B) (79.3 ) (5.0 ) (89.7 ) (19.5 ) Security and Detection (C ) 2.5 2.4 7.2 2.4 Total (loss) income from operations (64.6 ) 7.6 (51.2 ) 11.1 Total other income (loss), net 0.10 (0.9 ) (0.4 ) (4.9 ) (Loss) income before income taxes $ (64.5 ) $ 6.7 $ (51.6 ) $ 6.2 As of As of April 30, July 31, (in millions) 2017 2016 Identifiable total assets by segment: Medical Imaging $ 182.8 $ 191.1 Ultrasound 146.8 152.5 Security and Detection 42.6 49.8 Total reportable segment assets 372.2 393.4 Corporate assets (D) 193.1 165.6 Total identifiable assets $ 565.3 $ 559.0 (A) Includes restructuring charges of $0.2 million and $1.1 million for three months ended April 30, 2017 and April 30, 2016, respectively and $0.4 million and $5.1 million for nine months ended April 30, 2017 and April 30, 2016. (B) Includes restructuring charges of $1.8 million and $0.4 million for three months ended April 30, 2017 and April 30, 2016, respectively and $1.9 million and $1.7 million for nine months ended April 30, 2017 and April 30, 2016. Includes contingent consideration charges of $(2.1) million and $(10.2) million related to Oncura for three and nine months ended April 30, 2017, respectively. Includes asset impairment charges of $3.1 million related to Oncura intangible assets for three and nine months ended April 30, 2017. Includes asset impairment charges of $8.1 million related to PocketSonics intangible assets for three and nine months ended April 30, 2017. Includes goodwill impairment charges of $6.7 million and $16.5 million related to Oncura reporting unit for three and nine months ended April 30, 2017. Includes goodwill impairment charges of $55.1 million related to Ultrasound reporting unit for three and nine months ended April 30, 2017. Includes charges for the BK Medical matter of $0.0 million and $10.1 million for three and nine months ended April 30, 2016 . (C) Includes restructuring charges of $0.1 million and $0.3 million for three months ended April 30, 2017 and April 30, 2016, respectively and $0.1 million and $1.5 million for nine months ended April 30, 2017 and April 30, 2016. Includes asset impairment charges of $0.0 million and $0.6 million related to Pathfinder for three and nine months ended April 30, 2017. (D) Includes cash and cash equivalents of $144.9 million and $97.3 million as of April 30, 2017 and July 31, 2016, respectively.

Guarantees, commitments and c34

Guarantees, commitments and contingencies (Tables)	9 Months Ended
	Apr. 30, 2017
Commitments And Contingencies Disclosure [Abstract]
Product Warranty Liability	The following table presents our product warranty liability as of April 30, 2017: As of April 30, (in millions) 2017 Beginning balance $ 6.3 Provision 0.8 Settlements made in cash or in kind during the period (0.9 ) Ending balance $ 6.2

Accounts Receivable, Net - Addi

Accounts Receivable, Net - Additional Information (Detail)	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Sales Revenue, Net | Largest customers
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of total net revenue	61.00%	62.00%	63.00%	62.00%

Percentage of Net Product and E

Percentage of Net Product and Engineering Revenue from Major Customers (Detail) - Sales Revenue, Net - Largest customers	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Concentration Risk [Line Items]
Percentage of net product and engineering revenue	61.00%	62.00%	63.00%	62.00%
Philips
Concentration Risk [Line Items]
Percentage of net product and engineering revenue	14.00%	14.00%	14.00%	13.00%
Siemens AG
Concentration Risk [Line Items]
Percentage of net product and engineering revenue	11.00%	11.00%	12.00%	13.00%
L3
Concentration Risk [Line Items]
Percentage of net product and engineering revenue	11.00%	10.00%	10.00%
Toshiba
Concentration Risk [Line Items]
Percentage of net product and engineering revenue				11.00%

Percentage of Net Product and37

Percentage of Net Product and Engineering Revenue from Major Customers (Parenthetical) (Detail) - Sales Revenue, Net - Largest customers	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Concentration Risk [Line Items]
Percentage of net product and engineering revenue	61.00%	62.00%	63.00%	62.00%
L3
Concentration Risk [Line Items]
Percentage of net product and engineering revenue	11.00%	10.00%	10.00%
L-3 | Maximum
Concentration Risk [Line Items]
Percentage of net product and engineering revenue				10.00%
Toshiba
Concentration Risk [Line Items]
Percentage of net product and engineering revenue				11.00%
Toshiba | Maximum
Concentration Risk [Line Items]
Percentage of net product and engineering revenue		10.00%

Summary of Net Accounts Receiva

Summary of Net Accounts Receivable Greater than or Equal to 10% of Net Account Receivable Balance (Detail) (Accounts Receivable, Credit Concentration Risk) (Detail) - Accounts Receivable - Credit Concentration Risk	9 Months Ended	12 Months Ended
	Apr. 30, 2017	Jul. 31, 2016
L3
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of net accounts receivable	12.00%	17.00%
Philips
Accounts, Notes, Loans and Financing Receivable [Line Items]
Percentage of net accounts receivable	21.00%	15.00%

Components of Inventory (Detail

Components of Inventory (Detail) - USD ($) $ in Thousands	Apr. 30, 2017	Jul. 31, 2016
Inventory Disclosure [Abstract]
Raw materials	$ 68,400	$ 68,600
Work in process	47,500	45,600
Finished goods	28,400	31,300
Total inventory	$ 144,344	$ 145,513

Intangible Assets and Goodwil40

Intangible Assets and Goodwill - Additional Information (Detail)	Dec. 31, 2016USD ($)	Apr. 30, 2017USD ($)	Jan. 31, 2017USD ($)	Apr. 30, 2016USD ($)	Apr. 30, 2017USD ($)UnitSegment	Apr. 30, 2016USD ($)	Jul. 31, 2016USD ($)
Goodwill and Intangible Assets Disclosure [Line Items]
Indefinite lived intangible assets		$ 7,600,000			$ 7,600,000		$ 7,600,000
Amortization expense related to acquired intangible assets		1,900,000		$ 2,300,000	5,900,000	$ 6,300,000
Carrying value of intangible assets		19,800,000			19,800,000		37,600,000
Intangible assets impairment charge					11,900,000
Goodwill		2,344,000			$ 2,344,000		73,915,000
Number of Reporting Units | Unit					4
Number of Reportable Segments | Segment					3
Impairment of goodwill					$ 71,600,000
Intangible assets		27,406,000			27,406,000		45,194,000
Gain from adjustment of contingent consideration liability					(10,238,000)
Customer relationships
Goodwill and Intangible Assets Disclosure [Line Items]
Carrying value of intangible assets		16,000,000			16,000,000		21,900,000
Trade names
Goodwill and Intangible Assets Disclosure [Line Items]
Carrying value of intangible assets							900,000
Ultrasound
Goodwill and Intangible Assets Disclosure [Line Items]
Goodwill	$ 55,100,000	0			0		71,600,000
Impairment of goodwill	$ 0	55,100,000			71,600,000
Percentage of goodwill excess fair value over carrying value	25.00%
Intangible assets		9,300,000			9,300,000
Security and Detection
Goodwill and Intangible Assets Disclosure [Line Items]
Goodwill		500,000			500,000		500,000
Impairment of goodwill	$ 0
Medical Imaging
Goodwill and Intangible Assets Disclosure [Line Items]
Goodwill		1,800,000			1,800,000		$ 1,800,000
Impairment of goodwill	$ 0
Oncura
Goodwill and Intangible Assets Disclosure [Line Items]
Goodwill		0			0
Impairment of goodwill		6,700,000	$ 9,800,000
Fair value of contingent consideration obligation		0			0
Oncura | General and Administrative
Goodwill and Intangible Assets Disclosure [Line Items]
Gain from adjustment of contingent consideration liability		2,100,000			10,200,000
Oncura
Goodwill and Intangible Assets Disclosure [Line Items]
Gain from adjustment of contingent consideration liability		(2,100,000)			(10,200,000)
Fair value of contingent consideration obligation		0			0
Oncura | Ultrasound
Goodwill and Intangible Assets Disclosure [Line Items]
Carrying value of intangible assets		3,100,000			3,100,000
Intangible assets impairment charge		3,100,000
Oncura | Ultrasound | Customer relationships
Goodwill and Intangible Assets Disclosure [Line Items]
Intangible assets impairment charge		2,400,000
Oncura | Ultrasound | Trade names
Goodwill and Intangible Assets Disclosure [Line Items]
Intangible assets impairment charge		700,000
PocketSonics
Goodwill and Intangible Assets Disclosure [Line Items]
Gain from adjustment of contingent consideration liability		0			0
PocketSonics | Ultrasound
Goodwill and Intangible Assets Disclosure [Line Items]
Carrying value of intangible assets		8,100,000			$ 8,100,000
Intangible assets impairment charge		8,100,000
PocketSonics | Ultrasound | Technology
Goodwill and Intangible Assets Disclosure [Line Items]
Intangible assets impairment charge		$ 8,100,000
Minimum
Goodwill and Intangible Assets Disclosure [Line Items]
Intangible assets, estimated useful lives					1 year
Maximum
Goodwill and Intangible Assets Disclosure [Line Items]
Intangible assets, estimated useful lives					14 years

Finite-Lived Intangible Assets

Finite-Lived Intangible Assets (Detail) - USD ($) $ in Millions	9 Months Ended
	Apr. 30, 2017	Jul. 31, 2016
Finite-Lived Intangible Assets [Line Items]
Cost	$ 62.3	$ 78.9
Accumulated Amortization	42.5	41.3
Net	$ 19.8	37.6
Developed technologies
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Period	10 years
Cost	$ 17.7	29.9
Accumulated Amortization	13.9	15.1
Net	$ 3.8	14.8
Customer relationships
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Period	13 years
Cost	$ 43.7	47.1
Accumulated Amortization	27.7	25.2
Net	$ 16	21.9
Trade names
Finite-Lived Intangible Assets [Line Items]
Weighted-Average Amortization Period	3 years
Cost	$ 0.9	1.9
Accumulated Amortization	$ 0.9	1
Net		$ 0.9

Estimated Future Amortization E

Estimated Future Amortization Expense Related to Intangible Assets (Detail) - USD ($) $ in Millions	Apr. 30, 2017	Jul. 31, 2016
Commitments And Contingencies Disclosure [Abstract]
Remaining 2,017	$ 1.5
2,018	5
2,019	3.8
2,020	3.4
2,021	3
Thereafter	3.1
Net	$ 19.8	$ 37.6

Changes in the Carrying of Good

Changes in the Carrying of Goodwill by Reportable Segments (Detail) - USD ($)	Dec. 31, 2016	Apr. 30, 2017	Apr. 30, 2017
Goodwill
Goodwill, beginning balance			$ 73,915,000
Impairment losses			(71,600,000)
Goodwill		$ 73,900,000	73,900,000
Accumulated impairment losses		(71,600,000)	(71,600,000)
Goodwill, Ending Balance		2,344,000	2,344,000
Medical Imaging
Goodwill
Goodwill, beginning balance			1,800,000
Impairment losses	$ 0
Goodwill		1,800,000	1,800,000
Goodwill, Ending Balance		1,800,000	1,800,000
Ultrasound
Goodwill
Goodwill, beginning balance			71,600,000
Impairment losses	0	(55,100,000)	(71,600,000)
Goodwill		71,600,000	71,600,000
Accumulated impairment losses		(71,600,000)	(71,600,000)
Goodwill, Ending Balance	55,100,000	0	0
Security and Detection
Goodwill
Goodwill, beginning balance			500,000
Impairment losses	$ 0
Goodwill		500,000	500,000
Goodwill, Ending Balance		$ 500,000	$ 500,000

Assets and Liabilities Carried

Assets and Liabilities Carried at Fair Value and Measured on Recurring Basis (Detail) - USD ($) $ in Thousands	Apr. 30, 2017	Jul. 31, 2016	Apr. 30, 2016	Jul. 31, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 158,633	$ 118,697	$ 128,124	$ 123,800
Fair Value, Measurements, Recurring
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	158,600	118,700
Plan assets for deferred compensation	6,700	5,900
Total assets at fair value	165,300	124,600
Contingent consideration		12,200
Foreign currency forward contracts	500	300
Total liabilities at fair value	500	12,500
Fair Value, Measurements, Recurring | Quoted Prices in Active Markets (Level 1)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	158,600	118,700
Plan assets for deferred compensation	6,700	5,900
Total assets at fair value	165,300	124,600
Fair Value, Measurements, Recurring | Significant Other Observable Inputs (Level 2)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Foreign currency forward contracts	500	300
Total liabilities at fair value	$ 500	300
Fair Value, Measurements, Recurring | Significant Unobservable Inputs (Level 3)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Contingent consideration		12,200
Total liabilities at fair value		$ 12,200

Fair Value Measurements - Addit

Fair Value Measurements - Additional Information (Detail)	3 Months Ended	9 Months Ended
	Apr. 30, 2017USD ($)	Apr. 30, 2017USD ($)
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Adjustments in contingent consideration		$ (10,238,000)
PocketSonics
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Adjustments in contingent consideration	$ 0	0
Contingent consideration paid for business acquisitions	2,000,000
Oncura
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Adjustments in contingent consideration	(2,100,000)	(10,200,000)
Fair value of contingent consideration obligation	$ 0	$ 0

Derivative Instruments - Additi

Derivative Instruments - Additional Information (Detail) - Forward Contracts - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016	Jul. 31, 2016
Derivative [Line Items]
Unrealized loss on cash flow hedges	$ 0.3		$ 0.3		$ 0.2
Notional amount of cash flow hedge instruments	11.6		11.6		18.6
Cost of Revenue and Operating Expenses
Derivative [Line Items]
Realized gains (losses) on cash flow hedge instruments	(0.2)	$ (0.2)	(0.5)	$ (0.6)
Designated as Hedging Instrument
Derivative [Line Items]
Derivative liability, current	$ 0.5		$ 0.5		$ 0.3

Common Stock Repurchases - Addi

Common Stock Repurchases - Additional Information (Detail) - USD ($)	3 Months Ended	9 Months Ended	11 Months Ended	35 Months Ended
	Apr. 30, 2017	Apr. 30, 2017	Apr. 30, 2017	Apr. 30, 2017	May 26, 2016	Jun. 02, 2014
2016 Repurchase program
Stockholders Equity Note [Line Items]
Repurchase of common stock (in shares)	8,090	8,090	8,090
Repurchase of common stock	$ 600,000	$ 600,000	$ 600,000
Average purchase price of common stock	$ 71.46	$ 71.46	$ 71.46
2016 Repurchase program | Maximum
Stockholders Equity Note [Line Items]
Amount authorized for repurchase of Company's common stock					$ 15,000,000
2014 repurchase program
Stockholders Equity Note [Line Items]
Repurchase of common stock (in shares)	13,578	13,578		380,771
Repurchase of common stock	$ 1,000,000	$ 1,000,000		$ 30,000,000
Average purchase price of common stock	$ 74.08	$ 74.08		$ 78.76
2014 repurchase program | Maximum
Stockholders Equity Note [Line Items]
Amount authorized for repurchase of Company's common stock						$ 30,000,000
Repurchased stock of unused capacity						$ 1,000,000

Changes in Accumulated Other Co

Changes in Accumulated Other Comprehensive (Loss) Income (Detail) $ in Thousands	9 Months Ended
	Apr. 30, 2017USD ($)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	$ 531,177
Pre-tax change before reclassification to earnings	(2,100)
Amount reclassified to earnings	(200)
Income tax benefit (provision)	(100)
Ending balance	481,714
Unrealized Gain (Loss) on Foreign Currency Forward Contracts
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(200)
Amount reclassified to earnings	(200)
Income tax benefit (provision)	100
Ending balance	(300)
Unrealized Gains (Losses) on Pension Plan
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(4,900)
Pre-tax change before reclassification to earnings	200
Ending balance	(4,700)
Currency Translation Adjustment
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(3,400)
Pre-tax change before reclassification to earnings	(2,300)
Income tax benefit (provision)	(200)
Ending balance	(5,900)
Accumulated Other Comprehensive Income (Loss)
Accumulated Other Comprehensive Income (Loss) [Line Items]
Beginning balance	(8,500)
Ending balance	$ (10,900)

Share-based Compensation Expens

Share-based Compensation Expense (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense before tax	$ 2.2	$ 2.9	$ 6.4	$ 7.1
Income tax effect	(0.7)	(1)	(2)	(2.2)
Share-based compensation expense included in net income	1.5	1.9	4.4	4.9
Cost of Product Sales
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense before tax	0.1	0.1	0.3	0.4
Cost of Engineering Sales
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense before tax			0.1
Research and Product Development
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense before tax	0.4	0.6	1.2	1.8
Selling and Marketing
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense before tax	0.2	0.4	1.1	1.1
General and Administrative
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation expense before tax	$ 1.5	$ 1.8	$ 3.7	$ 3.8

Share-based Compensation - Addi

Share-based Compensation - Additional Information (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Intrinsic value of options exercised	$ 0		$ 2.2
Total fair value of restricted stock grants vested in period	0.9	$ 0.9	4.1	$ 5.3
Stock Option And Restricted Stock Bonus Plans
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Unrecognized compensation cost related to non-vested share-based compensation arrangements	$ 9.2		$ 9.2
Unrecognized compensation cost related to non-vested share-based compensation arrangements, weighted average period			1 year 2 months 12 days
Outstanding Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock options granted	0	0	0	0
Total Shareholders Return Performance-based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, grants in period	601	0	28,749	24,821
Non-GAAP EPS Performance-Based Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options, grants in period	594	0	62,626	32,444

Fair Value of TSR Performance-B

Fair Value of TSR Performance-Based Awards Valuation Assumption (Detail) - Restricted Stock Units (RSUs) - $ / shares		3 Months Ended		9 Months Ended
		Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Stock price	[1]	$ 73.60		$ 89.88	$ 84.06
Expected volatility	[2]	27.00%	0.00%	27.00%	26.40%
Risk-free interest rate	[3]	0.85%	0.00%	0.85%	1.04%
Expected annual dividend yield	[4]	0.00%	0.00%	0.00%	0.00%
Time Based Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value		$ 78.22	$ 74.18	$ 88.16	$ 82.66
Performance Based Restricted Stock Awards
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted average grant date fair value		$ 73.60		$ 86.88	$ 98.81
[1]	The stock price is the closing price of our common stock on the date of grant.
[2]	The expected volatility for each grant is determined based on the historical volatility for the peer group companies and our common stock over a period equal to the remaining term of the performance period from the date of grant for all awards.
[3]	The risk-free interest rate is determined based on the yield of zero-coupon U.S. Treasury securities for a period that is commensurate with the performance period.
[4]	Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.

Fair Value of TSR Performance52

Fair Value of TSR Performance-Based Awards Valuation Assumption (Parenthetical) (Detail)		3 Months Ended		9 Months Ended
		Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Expected annual dividend yield	[1]	0.00%	0.00%	0.00%	0.00%
[1]	Dividends are considered reinvested when calculating TSR. The dividend yield is therefore considered to be 0%.

Restructuring Charges - Additio

Restructuring Charges - Additional Information (Detail) $ in Thousands	3 Months Ended		9 Months Ended		12 Months Ended
	Apr. 30, 2017USD ($)	Apr. 30, 2016USD ($)	Apr. 30, 2017USD ($)	Apr. 30, 2016USD ($)	Jul. 31, 2017USD ($)Employee
Restructuring Cost and Reserve [Line Items]
Restructuring charge	$ 2,080	$ 1,839	$ 2,379	$ 8,269
Restructuring adjustments			100
Fiscal Year 2017 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring charge	2,100		2,500
Fiscal Year 2017 Restructuring Plan | Scenario, Forecast
Restructuring Cost and Reserve [Line Items]
Expected reduction in number of employees | Employee					130
Restructuring charge					$ 5,000
Fiscal Year 2016 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring charge		$ 1,800		$ 8,300
Restructuring adjustments	$ 0		$ (100)

Summary of Charges Related to A

Summary of Charges Related to Accrued Restructuring Activities (Detail) - USD ($) $ in Millions		3 Months Ended		9 Months Ended
		Apr. 30, 2017		Apr. 30, 2017
Restructuring Cost and Reserve [Line Items]
Balance at beginning period		$ 1.4		$ 5.2
Restructuring charge		2.1		2.5
Adjustments				(0.1)
Cash payments		(1.1)		(5.2)
Balance at end period		2.4		2.4
Employee Severance and Benefits
Restructuring Cost and Reserve [Line Items]
Balance at beginning period		1.4	[1]	5.2	[2]
Restructuring charge		2.1	[1]	2.5	[2]
Adjustments	[2]			(0.1)
Cash payments		(1.1)	[1]	(5.2)	[2]
Balance at end period	[1],[2]	$ 2.4		$ 2.4
[1]	Restructuring charges in fiscal year 2017 includes $2.1 million with respect to the Fiscal Year 2017 Restructuring Plan. All other activity pertains to the Fiscal Year 2016 Restructuring Plan.
[2]	Restructuring charges in fiscal year 2017 includes $2.4 million with respect to the Fiscal Year 2017 Restructuring Plan. All other activity pertains to the Fiscal Year 2016 Restructuring Plan.

Summary of Charges Related to55

Summary of Charges Related to Accrued Restructuring Activities (Parenthetical) (Detail) - USD ($) $ in Millions	3 Months Ended	9 Months Ended
	Apr. 30, 2017	Apr. 30, 2017
Restructuring Cost and Reserve [Line Items]
Restructuring charge	$ 2.1	$ 2.5
Fiscal Year 2017 Restructuring Plan
Restructuring Cost and Reserve [Line Items]
Restructuring charge	$ 2.1	$ 2.4

Restructuring and Related Charg

Restructuring and Related Charges by Segment (Detail) - USD ($) $ in Millions	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges	$ 2.1	$ 1.8	$ 2.4	$ 8.3
Medical Imaging
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges	0.2	1.1	0.4	5.1
Ultrasound
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges	1.8	0.4	1.9	1.7
Security and Detection
Restructuring Cost and Reserve [Line Items]
Restructuring and related charges	$ 0.1	$ 0.3	$ 0.1	$ 1.5

Computation of Basic and Dilute

Computation of Basic and Diluted Net Income Per Share (Detail) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands		3 Months Ended		9 Months Ended
		Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Earnings Per Share [Abstract]
Net (loss) income		$ (59,664)	$ 4,970	$ (49,618)	$ 3,361
Weighted average number of common shares outstanding-basic		12,486	12,392	12,457	12,412
Effect of dilutive securities:
Stock options and restricted stock units			161		211
Weighted average number of common shares outstanding-diluted		12,486	12,553	12,457	12,623
Basic net (loss) income per share		$ (4.78)	$ 0.40	$ (3.98)	$ 0.27
Diluted net (loss) income per share		$ (4.78)	$ 0.40	$ (3.98)	$ 0.27
Anti-dilutive shares related to outstanding stock options and unvested restricted stock	[1]	242	87	228	5
[1]	These shares related to outstanding stock options and unvested restricted stock were not included in our calculations of diluted earnings per share, as the effect of including them would be anti-dilutive.

Provision for Income Taxes and

Provision for Income Taxes and Effective Tax Rate (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016
Income Tax Disclosure [Abstract]
(Benefit)/provision for income taxes	$ (4,882)	$ 1,722	$ (1,934)	$ 2,863
Effective tax rate	8.00%	26.00%	4.00%	46.00%

Income Taxes - Additional Infor

Income Taxes - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016	Jul. 31, 2016
Income Taxes [Line Items]
U.S. Federal statutory tax rate	35.00%	35.00%	35.00%	35.00%
Discrete tax benefit		$ (200,000)		$ 1,100,000
Unrecognized tax benefits, accrued interest and penalties	$ 300,000		$ 300,000		$ 400,000
Unrecognized tax benefits, for uncertain tax positions	6,900,000		6,900,000
Maximum
Income Taxes [Line Items]
Discrete tax benefit	$ 500,000		$ 900,000

Reportable Segment Information

Reportable Segment Information (Detail) - USD ($) $ in Thousands		3 Months Ended		9 Months Ended
		Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016	Jul. 31, 2016
Product revenue:
Product revenue		$ 120,791	$ 126,376	$ 371,373	$ 366,443
Engineering revenue:
Engineering revenue		1,371	1,604	3,448	4,354
Net revenue:
Total net revenue		122,162	127,980	374,821	370,797
Income (loss) from operations:
Total (loss) income from operations		(64,603)	7,626	(51,195)	11,123
Total other income (loss), net		100	(900)	(400)	(4,900)
(Loss) income before income taxes		(64,546)	6,692	(51,552)	6,224
Identifiable total assets by segment:
Assets		567,677		567,677		$ 632,897
Total Identifiable Assets
Identifiable total assets by segment:
Assets		565,300		565,300		559,000
Reportable segments
Identifiable total assets by segment:
Assets		372,200		372,200		393,400
Corporate
Identifiable total assets by segment:
Identifiable assets (excluding goodwill)	[1]	193,100		193,100		165,600
Medical Imaging
Product revenue:
Product revenue		68,200	71,900	205,900	208,700
Engineering revenue:
Engineering revenue		1,300	900	3,100	2,600
Net revenue:
Total net revenue		69,500	72,900	209,000	211,300
Income (loss) from operations:
Total (loss) income from operations		12,200	10,200	31,300	28,200
Medical Imaging | Reportable segments
Identifiable total assets by segment:
Assets		182,800		182,800		191,100
Ultrasound
Product revenue:
Product revenue		34,800	36,800	110,700	115,900
Engineering revenue:
Engineering revenue			800	200	1,700
Net revenue:
Total net revenue		34,800	37,600	110,900	117,600
Income (loss) from operations:
Total (loss) income from operations		(79,300)	(5,000)	(89,700)	(19,500)
Ultrasound | Reportable segments
Identifiable total assets by segment:
Assets		146,800		146,800		152,500
Security and Detection
Product revenue:
Product revenue		17,800	17,600	54,800	41,800
Engineering revenue:
Engineering revenue		100	(100)	100	100
Net revenue:
Total net revenue		17,900	17,500	54,900	41,900
Income (loss) from operations:
Total (loss) income from operations		2,500	$ 2,400	7,200	$ 2,400
Security and Detection | Reportable segments
Identifiable total assets by segment:
Assets		$ 42,600		$ 42,600		$ 49,800
[1]	Includes cash and cash equivalents of $144.9 million and $97.3 million as of April 30, 2017 and July 31, 2016, respectively.

Reportable Segment Informatio61

Reportable Segment Information (Parenthetical) (Detail) - USD ($) $ in Thousands	3 Months Ended		9 Months Ended
	Apr. 30, 2017	Apr. 30, 2016	Apr. 30, 2017	Apr. 30, 2016	Jul. 31, 2016	Jul. 31, 2015
Segment Reporting Information [Line Items]
Restructuring charge	$ 2,080	$ 1,839	$ 2,379	$ 8,269
Asset impairment charges	73,051		83,474
Cash and cash equivalents	158,633	128,124	158,633	128,124	$ 118,697	$ 123,800
Corporate
Segment Reporting Information [Line Items]
Cash and cash equivalents	144,900		144,900		$ 97,300
Pathfinder
Segment Reporting Information [Line Items]
Asset impairment charges	0		600
Medical Imaging
Segment Reporting Information [Line Items]
Restructuring charge	200	1,100	400	5,100
Ultrasound
Segment Reporting Information [Line Items]
Restructuring charge	1,800	400	1,900	1,700
Goodwill impairment charges	55,100		55,100
Oncura
Segment Reporting Information [Line Items]
Contingent consideration charges	(2,100)		(10,200)
Asset impairment charges	3,100		3,100
Goodwill impairment charges	6,700		16,500
PocketSonics
Segment Reporting Information [Line Items]
Asset impairment charges	8,100		8,100
BK Medical System
Segment Reporting Information [Line Items]
Impairment charges	0		10,100
Security and Detection
Segment Reporting Information [Line Items]
Restructuring charge	$ 100	$ 300	$ 100	$ 1,500

Guarantees, Commitments and C62

Guarantees, Commitments and Contingencies - Additional Information (Detail) CAD in Millions	Jan. 03, 2017CAD	Nov. 23, 2015USD ($)	Oct. 11, 2011USD ($)	Apr. 30, 2017USD ($)	Apr. 30, 2017USD ($)	Jul. 31, 2016USD ($)
Commitments and Contingencies Disclosure [Line Items]
Liabilities related to agreements				$ 0	$ 0
Revolving credit agreement period		5 years
Ultrasonix | Pending Litigation [Member]
Commitments and Contingencies Disclosure [Line Items]
Unpaid and accelerated rent legal claim | CAD	CAD 1
Accrued charge in connection				$ 400,000	$ 400,000
Revolving Credit Facility
Commitments and Contingencies Disclosure [Line Items]
Credit facility maximum borrow capacity		$ 100,000,000
Credit facility, expiry date					Nov. 23, 2020
Leverage ratio				0.40%	0.40%
Interest expense					$ 0
Credit facility transaction costs incurred				$ 500,000	$ 500,000
Credit facility, maturity period					5 years
Line of credit amount outstanding				0	$ 0	$ 0
Revolving Credit Facility | Other Revolving Credit Facilities
Commitments and Contingencies Disclosure [Line Items]
Credit facility available borrowing capacity				1,200,000	$ 1,200,000	1,200,000
Revolving Credit Facility Termination | Facility Exit Costs
Commitments and Contingencies Disclosure [Line Items]
Revolving credit agreement period			5 years
Credit facility maximum borrow capacity			$ 100,000,000
Credit facility, expiry date					Oct. 11, 2011
Product Extended Warranty Contracts
Commitments and Contingencies Disclosure [Line Items]
Deferred revenue				300,000	$ 300,000	$ 200,000
Minimum
Commitments and Contingencies Disclosure [Line Items]
Standard product warranty term					12 months
Minimum | Ultrasonix | Pending Litigation [Member]
Commitments and Contingencies Disclosure [Line Items]
Reasonable estimate of liability				$ 400,000	$ 400,000
Minimum | Revolving Credit Facility
Commitments and Contingencies Disclosure [Line Items]
Credit facility commitment fee percentage		0.20%
Interest coverage ratio				300.00%	300.00%
Minimum | Revolving Credit Facility | LIBOR Rate
Commitments and Contingencies Disclosure [Line Items]
Variable interest rate		1.25%
Minimum | Revolving Credit Facility | Base Rate
Commitments and Contingencies Disclosure [Line Items]
Variable interest rate		0.00%
Maximum
Commitments and Contingencies Disclosure [Line Items]
Standard product warranty term					60 months
Maximum | Ultrasonix | Pending Litigation [Member]
Commitments and Contingencies Disclosure [Line Items]
Reasonable estimate of liability				$ 700,000	$ 700,000
Maximum | Revolving Credit Facility
Commitments and Contingencies Disclosure [Line Items]
Aggregate available credit amount under specified circumstances		$ 200,000,000
Credit facility commitment fee percentage		0.35%
Leverage ratio of total debt to earnings before interest, taxes, depreciation, and amortization or EBITDA					275.00%
Maximum | Revolving Credit Facility | LIBOR Rate
Commitments and Contingencies Disclosure [Line Items]
Variable interest rate		1.75%
Maximum | Revolving Credit Facility | Base Rate
Commitments and Contingencies Disclosure [Line Items]
Variable interest rate		1.00%

Product Warranty Liability (Det

Product Warranty Liability (Detail) $ in Millions	9 Months Ended
	Apr. 30, 2017USD ($)
Product Warranties Disclosures [Abstract]
Beginning balance	$ 6.3
Provision	0.8
Settlements made in cash or in kind during the period	(0.9)
Ending balance	$ 6.2

Subsequent Events - Additional

Subsequent Events - Additional Information (Detail) - Subsequent Event	Jun. 01, 2017$ / shares
Subsequent Event [Line Items]
Dividend declaration date	Jun. 1, 2017
Dividend declared	$ 0.10
Dividend payable date	Jun. 30, 2017
Dividend record date	Jun. 16, 2017